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ABSTRACT

Larrick, Brienna M. Ph.D., Purdue University, May 2016. 1,25-Dihydroxyvitamin
D Regulation of Triacylglycerol Accumulation in Differentiated Adipocytes. Major
Professor: Dorothy Teegarden.
Obesity is a major public health concern, both in the United States and
worldwide. Therefore, identification of measures by which obesity may be
prevented and reversed is of high priority. Epidemiological studies consistently
demonstrate an inverse relationship between serum 25(OH)D levels, an indicator
of vitamin D status, and measures of adiposity. These data suggest that vitamin
D may play a role in the prevention of excessive adiposity. However, whether
vitamin D impacts lipid storage and metabolism in terminally differentiated
adipocytes is not yet known. The purpose of this work was to determine the
impact of 1,25-dihydroxyvitamin D (1,25(OH)2D), the bioactive vitamin D
metabolite, on triacylglycerol accumulation and lipid and glucose metabolism in
differentiated adipocytes. To study this, 3T3-L1 adipocytes were differentiated for
9 days, followed by stimulation with 1,25(OH)2D (10 nM) or vehicle for 1-7 days.
Results indicate that 1,25(OH)2D stimulates a 21% reduction in TAG
accumulation in differentiated 3T3-L1 adipocytes after 4 days (P=0.01). This
occurs despite a significant increase in fatty acid uptake (P<0.01), assessed
using BODIPY FL C16, and with concomitant stimulation of PKA-dependent

xiii
glycerol release (P<0.01), which is typically indicative of lipolysis. Additionally, we
demonstrate that 1,25(OH)2D stimulates a 2.5-fold increase in complete fatty acid
oxidation (P<0.01), assessed by quantifying the production of 14CO2 from [1-14C]
palmitic acid. These results suggest a novel mechanism by which 1,25(OH)2D
may be protective against excessive adiposity. In addition to its impact on fatty
acid metabolism, the impact of 1,25(OH)2D on glucose metabolism was also
examined. Glucose contributes significantly to the intracellular TAG pool, serving
as a substrate for both fatty acid synthesis as well as glycerol production to
support TAG synthesis. The results indicate that 1,25(OH)2D reduces the
incorporation of D-[U-13C]glucose incorporation into palmitic, palmitoleic, stearic,
and oleic acids (P=0.03), determined by liquid chromatography-mass
spectrometry (LC-MS). Interestingly, [13C2]acetate incorporation into these fatty
acids was reduced by only 10% (p<0.01), suggesting that while de
novo lipogenesis is slightly inhibited in response to 1,25(OH)2D, the contribution
of glucose specifically as a substrate for fatty acid synthesis is reduced. Study of
glucose uptake and disposal as lactate revealed that these two processes are
not impacted by 1,25(OH)2D, suggesting that glucose may instead be used for
the synthesis of glycerol. Indeed, inhibition of glycolysis to reduce substrate
availability for glycerol synthesis completely prevented 1,25(OH)2D-stimulation of
glycerol release. These data suggest that rather than stimulating TAG hydrolysis,
1,25(OH)2D stimulates disposal of glucose as glycerol, while reducing its
utilization as a substrate for fatty acid synthesis. While the mRNA expression of
pyruvate carboxylase (PC) is reduced by 40% in response to 1,25(OH)2D
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(P<0.01), suggesting that 1,25(OH)2D may limit pyruvate entry into the TCA
cycle, at this time it is not clear whether this underlies the 1,25(OH)2D-stimulated
changes in glucose metabolism and TAG storage. In conclusion, 1,25(OH)2D
stimulates fatty acid oxidation in 3T3-L1 adipocytes, and reduces the contribution
of glucose to the fatty acid pool, likely by stimulating glucose disposal as glycerol.
These results demonstrate that 1,25(OH)2D regulates both fatty acid and glucose
metabolism in differentiated 3T3-L1 adipocytes to reduce TAG storage. These
novel findings demonstrate a mechanism by with 1,25(OH)2D may protect
against excessive fat mass accumulation, and provide support for the inverse
relationship between vitamin D and obesity.
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CHAPTER 1. LITERATURE REVIEW

1.1

Obesity and Associated Metabolic Disorders

Obesity has become a major public health concern, with over 36% of
adults and 17% of children and adolescents in the United States considered
obese (1). Individuals who are obese are at increased risk for developing chronic
diseases and metabolic disorders, as well as certain types of cancer (2).
Additionally, it is estimated that medical costs associated with obesity account for
over 20% of all annual health care spending in the United States, and that direct
and indirect costs from obesity exceed $275 billion annually (3). Because of
these devastating physical, psychological, and financial costs of obesity, it is
imperative that effective measures to prevent and reverse obesity are identified.
Several measures exist by which individuals may be classified according
to their weight status and associated disease risk. Body mass index (BMI) is a
quick and inexpensive method of weight assessment, and is positively correlated
with metabolic disorders that are associated with obesity. Therefore, BMI is often
used as a screening tool for categorizing individuals by weight. Body mass index
is calculated by dividing an individual’s weight in kilograms by the square of
height in meters. While BMI is not a direct measure of adiposity, BMI does
correlate with direct measures of body fat, including dual energy x-ray
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absorptiometry (DEXA), bioelectrical impedance, densitometry, and skinfold
thickness measurements (4, 5). For adults 20 years and older, BMI is used to
categorize individuals as underweight (BMI < 18.5), normal weight (BMI 18.524.9), overweight (BMI 25.0-29.9), or obese (BMI >30.0) (2). Epidemiological
data show a modest increased risk of mortality when BMI reaches above 25
kg/m2 (6-8), and a 50-100% risk of all-cause mortality when BMI reaches 30
kg/m2 (7, 8).
While BMI serves as a convenient and inexpensive measure of weight
assessment, it does not distinguish between excessive adipose and muscle
mass, and is therefore not diagnostic individual of health risk (9). A more
accurate representation of an individual’s health risk may be obtained by
assessing percent body fat. The “gold standard” for measuring body fat is DEXA,
but this method is expensive and not always accessible. Estimates of percent
body fat may also be obtained using handheld or scale instruments that measure
bioimpedance, or by measurements of skinfold (10). To avoid elevated weightassociated health risks, the recommended body fat percentage ranges for men
and women are 12-20% and 20-30%, respectively (11).
There are many diseases and health conditions associated with obesity.
Individuals who are obese are more likely than lean individuals to experience
sleep apnea, depression, anxiety, and osteoarthritis (2, 12, 13). Further,
metabolic disorders such as hypertension, dyslipidemia, coronary artery disease,
and type 2 diabetes are more prevalent among those who are obese, as are
certain types of cancer such as that of the breast, colon, kidney, gallbladder, and

3
liver (2, 14). Adipose tissue dysfunction often underlies obesity-associated
metabolic disorders, and modulation of adipose tissue metabolism has become a
target for combating obesity and associated chronic diseases.
1.1.1 Adipose Tissue Physiology

1.1.1.1 Characteristics of Adipose Tissue
For the vast majority of individuals, adipose tissue is the largest energy
reservoir in the body (15). In animals, approximately one-third of the cells found
in adipose tissue are adipocytes, while the remaining two-thirds are a
combination of fibroblasts, preadipocytes, stem cells, as well as nerve tissue and
vasculature (16). Historically, adipose tissue was considered to be an organ
devoted mainly to energy storage and thermal regulation, while serving as a
source of cushioning to protect internal organs (17). However, the complexity of
this tissue has been identified in recent years, and it is now known that functions
of adipose tissue also include regulation of appetite, insulin sensitivity and
glucose homeostasis, lipid metabolism, inflammation and immunity, as well as
angiogenesis and blood pressure (17, 18).
In humans, adipose tissue is organized in discrete anatomical depots:
subcutaneous and visceral. Adipose tissue ranges from 5-60% of total body
mass, with subcutaneous adipose tissue (SAT) accounting for 80% or more of
the total fat mass (19). The subcutaneous adipose tissue lies under the skin and
includes abdominal, gluteal, and femoral adipose depots (19). Accumulation of
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subcutaneous fat mass, or peripheral obesity, is thought to be protective against
metabolic disease (20-26).
On the other hand, visceral adipose tissue (VAT) is associated with
digestive organs, and represents 10-20% of the total fat mass in men, and 5-10%
of that in women. Visceral adipose depots include the omental, which associates
with the stomach, the intestine-associated mesenteric, and the epiploic, which
can be found along the colon (19). Excessive accumulation of visceral adipose
tissue, termed “central obesity,” is associated with risk of metabolic disorders
(20-24, 26). It is thought that VAT confers elevated risk of metabolic disorders
because of its direct access to the portal vein; hepatocytes are exposed to high
levels of fatty acids freed by lipolysis from VAT, which may lead to hepatic insulin
resistance, hepatic glucose production and fasting hyperglycemia (27). Further,
production of proinflammatory cytokines has been found to be higher in VAT than
in SAT depots (28), contributing to the increased metabolic disease risk with
excessive VAT accumulation.
1.1.1.2 Functions of Adipose Tissue
One of the longest-known functions of adipose tissue is maintenance of
energy homeostasis. Adipocytes can store excess energy in cytoplasmic lipid
droplets, in the form of triacylglycerol (TAG). Postprandially, or in response to
overnutrition, this function prevents ectopic lipid deposition in tissues such as the
liver, heart, and skeletal muscle, and prevents lipotoxicity in these organs (29).
Conversely, during fasting, or when energy demand exceeds energy intake, TAG
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stores may be hydrolyzed to release fatty acids from the cell for use by other
tissues. The storage and hydrolysis of TAG in adipocytes prevents excess
circulating energy substrates when food is plentiful, and ensures constant energy
availability during prolonged periods of fasting (30).
While adipose tissue was originally considered an inert energy storage
reservoir that also provides temperature and mechanical insulation, adipose
tissue has recently recognized as an active endocrine organ (31). Adipose tissue
secretes a variety of bioactive peptides, called adipokines, which participate in
the regulation of feeding behavior, glucose and lipid metabolism, energy
homeostasis, immunity, inflammation, adipogenesis and vascular function (32).
Adipokines secreted by adipose tissue include adiponectin, leptin, resistin,
adipsin, and visfatin, as well as cytokines such as IL-6 and TNFα. These factors
that are secreted by adipocytes act locally, peripherally, and centrally to impact
tissue metabolism and cross-talk (15).
1.1.1.3 Adipocyte Biology
While adipocytes account for approximately one-third of the cells found in
adipose tissue, adipocytes constitute approximately 90% of the total tissue
volume due to their large size. Three distinct types of adipocytes exist: white,
brown, and beige. Phenotypically, white adipocytes are large, round, and
unilocular (i.e. they contain one large lipid droplet). White adipocytes do not
express uncoupling protein-1 (UCP-1), and they have a low mitochondrial
density. Their main functions are to act as an energy reservoir and as an
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endocrine organ. Brown adipocytes are multilocular, exhibit high levels of UCP-1
expression, and have a high mitochondrial density, which confers their brown
color. Brown adipocytes also function as a source of thermogenesis. Beige, or
brite, adipocytes exhibit characteristics that are intermediate to brown and white
adipocytes. Beige adipocytes exhibit UCP-1 expression, and have multiple lipid
droplets. The major functions and characteristics of these different types of
adipocytes are still under investigation (33).
1.1.1.3.1 White Adipocytes
The white adipocyte is the most abundant type of adipocyte in the adipose
tissue. Its major functions are to store and release fuel during times of energy
excess and deprivation, and to contribute to the endocrine functions of adipose
tissue. Lipogenesis and lipolysis within the adipocyte are regulated in the short
term by hormonal signals in circulation. However, long-term maintenance of
adipose tissue and changes in energy storage require changes in both size and
number of adipocytes. An increase in cell number, or hyperplasia, is achieved by
stimulating the differentiation of preadipocytes, which are also found in adipose
tissue.
Much of what is known about adipocyte differentiation was determined
using the murine 3T3-L1 preadipocyte cell line. This cell line is one of the most
common, and best characterized, models used to investigate adipocyte
development and function. When injected into mice, 3T3-L1 preadipocytes
differentiate and form fat pads that are indistinguishable from the mouse adipose
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tissue (34). Differentiation of 3T3-L1 post-confluent preadipocytes can be
achieved using a differentiation cocktail consisting of insulin, a glucocorticoid, an
agent that stimulates intracellular cyclic AMP (cAMP) formation, and fetal bovine
serum (35). Typically, a cocktail of insulin, dexamethasone (DEX), a synthetic
glucocorticoid agonist, and isomethylbutylxanthine (IBMX), a phosphodiesterase
inhibitor used to stimulate intracellular cAMP accumulation, is used to stimulate
adipogenesis in 3T3-L1 adipocytes (36).
Preadipocyte differentiation occurs following a temporal cascade of
transcriptional events (Figure 1.1) (37). Cell-to-cell contact at confluence
stimulates the expression of lipoprotein lipase (LPL) and type IV collagen, early
markers of adipocyte differentiation (38, 39). Within one hour after addition of the
differentiation cocktail, transient expression (lasting 2-6 hours) of c-fos, c-jun, and
c-myc is observed, as well as the expression of CCAAT/enhancer binding protein
(C/EBP) β and δ (40). Within 24 hours after administration of the differentiation
cocktail, postconfluent mitosis and subsequent growth arrest occur, after which
cells are committed to becoming adipocytes (41). Upon removal of the
differentiation cocktail, expression of C/EBPβ and δ dissipate within 2-8 days
(42). However, their transient expression and activity are needed for the
expression of peroxisome proliferator-activated receptor γ (PPARγ) (43, 44) and
C/EBPα (45, 46), which are induced 2 days after initiation of differentiation and
are maximally expressed by 3-5 days following initiation of differentiation. The
sustained expression of both PPARγ and C/EBPα are necessary for the
subsequent expression of adipocyte- specific genes, such as those involved in
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Figure 1.1. Adipocyte differentiation transcriptional cascade. C/EBP: CCAATenhancer-binding protein; DEX: dexamethasone; IBMX: 3-isobutyl-1methylxanthine. Adapted from “Adipocyte differentiation and gene expression,”
by Ntambi JM and Young-Cheul K., The Journal of Nutrition 2000; 130: 3122S3126S. Adapted with permission from the American Society for Nutrition.
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lipid and glucose metabolism, and for development of the mature adipocyte
phenotype (47).
1.1.1.3.2 Brown Adipocytes
There are many characteristics that distinguish brown from white
adipocytes, namely, high mitochondrial density, UCP-1 expression, and the
presence of many small lipid droplets (33). The high levels of mitochondrial UCP1 expression in brown adipocytes cause uncoupling of the mitochondrial
respiratory chain from ATP production, allowing energy to dissipate as heat by a
process called non-shivering thermogenesis (48). This process is stimulated in
response to β-adrenergic receptor stimulation, such as that which occurs when
noradrenaline is released upon cold exposure (49, 50). In mice, brown
adipocytes are found in inter-scapular, sub-scapular, and cervical regions (51).
While originally thought to be only present in infant humans, recent studies
employing 18F-fluorodeoxyglucose (FDG) positron emission
tomography/computed tomography (PET-CT) analysis of glucose uptake have
identified BAT in adult humans (52). Further, it has been demonstrated that the
abundance of BAT is inversely correlated with BMI and total adipose mass,
highlighting the therapeutic potential of targeting BAT to combat obesity (52-57).
Several studies suggest independent lineages for the developmental origins of
white and brown adipocytes; specifically, that brown adipocytes share a common
lineage with myogenic cells (58-62). However, the origins of brown and white
adipocytes remain incompletely understood, and whether selectively increasing
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BAT mass and/or activity in humans is achievable, in order to combat obesity, is
under current investigation (33).
1.1.1.3.3 Beige Adipocytes
A third type of adipocyte is the beige, or “brite” (brown-in-white) adipocyte.
These adipocytes resemble brown adipocytes in that they express UCP-1, are
multilocular, and have higher mitochondrial density than white adipocytes (63,
64). Under basal conditions, beige adipocytes exhibit a phenotype similar to
white adipocytes. However, in response to cold stimulation, these adipocytes are
“browned,” and display characteristics similar to the brown adipocyte (33). While
the primary function of beige adipocytes appears to be thermogenesis, the
characterization of this cell type is under investigation.
1.1.1.4 Adipocyte Lipid Metabolism
Fatty acids serve a variety of functions within all cells, including as an
energy source, as a precursor for cellular membranes, and as precursors for
signaling molecules. In adipocytes, fatty acids are also stored in the form of TAG,
so that during times of energy deficit they may be released for use by other
tissues. As such, the adipocyte must maintain tight regulation over the processes
used to take up, synthesize, store, and release fatty acids.
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1.1.1.4.1 Fatty Acid Uptake
Fatty acids can be taken up as free fatty acids (FFA), which circulate
bound to serum albumin, or can be obtained through the hydrolysis of TAG,
which are carried in circulation by lipoproteins such as chylomicrons or very lowdensity lipoproteins (VLDL). Postprandially, or after a meal, fatty acids obtained
from the diet are packaged by enterocytes into chylomicrons, which first enter
circulation within the lymphatic system, followed by entry into the bloodstream.
These chylomicrons, along with very low density lipoproteins (VLDL) secreted by
the liver, transport fatty acids in the form of TAG to peripheral tissues such as
adipose tissue, skeletal muscle, and the heart. Chylomicrons and VLDLs are
spherical particles featuring a hydrophobic lipid core containing neutral lipids
such as TAG, cholesterol esters, and sterol esters, surrounded by a polar lipid
surface layer that contains phospholipids and free cholesterol, as well as
apolipoproteins that collectively provide a hydrophilic interface with the aqueous
surroundings in circulation (65, 66).
Chylomicrons and VLDL are relatively large in size, having diameters of
100-1200 nm and 30-80 nm, respectively (66). In order to enter the cell, TAG
must be hydrolyzed to fatty acids intravascularly by lipoprotein lipase (LPL).
Intravascular lipolysis removes up to 90% of TAG from the circulating lipoprotein,
allowing fatty acids to be taken up by peripheral tissues. The apolipoprotein
remnant is taken up by hepatocytes, for use in VLDL synthesis (67).
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Uptake of fatty acids by cells can occur by several mechanisms (68).
While long chain fatty acids may diffuse passively across phospholipid bilayers
(69), a variety of facilitated transport mechanisms by integral or membraneassociated proteins have been identified (70). To enter the cell, the fatty acid
must first dissociate from the lipoprotein or serum albumin, diffuse through the
outer aqueous phase and insert into the outer plasma membrane, translocate or
“flip-flop” from the outer to the inner plasma membrane, and dissociate from the
inner membrane to the aqueous cytosolic phase of the cell (71). Proteins at the
plasma membrane such as fatty acid transport protein (FATP), fatty acid binding
protein (FABP), caveolin-1, and CD36 have been implicated in the uptake and
utilization of fatty acids (68, 71). However, the precise mechanisms of FA
transport across cell membranes, and the relative contributions of diffusion- and
protein-mediated uptake, remain a source of interest and controversy (71, 72).
1.1.1.4.2 Fatty Acid Synthesis
In addition to the uptake of exogenous fatty acids, the adipocyte may
synthesize fatty acids de novo from non-lipid precursors such as glucose (Figure
1.2). The key transcription factor regulating expression of genes involved in
lipogenesis is sterol regulatory element-binding protein-1c (SREBP-1c), and the
primary enzymes involved in fatty acid synthesis are fatty acid synthase (FAS)
and acetyl-CoA carboxylase (ACC) (73). When glucose is abundant, increased
flux through glycolysis leads to excess citrate in the tricarboxylic acid (TCA)
cycle, which is then redirected to the cytosol and converted to acetyl-CoA for
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Figure 1.2. Summary of fatty acid and triacylglycerol synthesis in adipocytes.
ACC: acetyl-CoA carboxylase; ACL: ATP-citrate lyase; AGPAT: 1-acylglycerol-3phosphate acyltransferase; DGAT: diacylglycerol acyltransferase; FAS: fatty acid
synthase; GPAT: glycerol-3-phosphate acyltransferase; GPDH: glycerol-3phosphate dehydrogenase; MDH: malate dehydrogenase; ME: malic enzyme;
OAA: oxaloacetate; PC: pyruvate carboxylase; PDH; pyruvate dehydrogenase;
PEPCK: phosphoenolpyruvate carboxykinase.
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fatty acid synthesis (74). Cytosolic acetyl-CoA is carboxylated by ACC to form
malonyl-CoA. Malonyl-CoA joined to acetyl-CoA by FAS, and this hydrocarbon
chain is elongated to form palmitic acid, which may then be further elongated or
desaturated, and esterified with G3P to form TAG (15). In humans, de novo
lipogenesis accounts for approximately 20% of newly formed TAG-palmitate (75),
highlighting the significance of adipose tissue DNL contribution to total fat mass
stores.
1.1.1.4.3 Triacylglycerol Synthesis
Whether obtained from circulation or synthesized de novo, intracellular
fatty acids are esterified to glycerol-3-phosphate (G3P) for storage in lipid
droplets as TAG. In lipogenic tissues such as adipose tissue and the liver,
glycerol-3-phosphate may be derived from three sources: glycolysis,
glyceroneogenesis, and glycerol kinase activity (76). During glycolysis, glucose
that has been taken up into the cell is phosphorylated and through a series of
reactions converted to G3P and dihydroxyacetone phosphate (DHAP). The
DHAP may be converted to G3P by glycerol phosphate dehydrogenase (GPDH)
to form G3P, which may then be used for TAG synthesis. In humans,
approximately 20-25% of glucose taken up by adipocytes following an overnight
fast is used for G3P synthesis and incorporation into TAG (77).
Alternatively, G3P may be synthesized from non-glucose precursors such
as pyruvate, lactate, and amino acids by a process called glyceroneogenesis.
Pyruvate is carboxylated to oxaloacetate (OAA), which then exits the

15
mitochondria and is decarboxylated by cytoplasmic phosphoenolpyruvate
carboxykinase (PEPCK) to form phosphoenolpyruvate (PEP), the rate-limiting
step of glyceroneogenesis (78). Phosphoenolpyruvate is then converted
glyceraldehyde-3-phosphate followed by DHAP, which can then be converted to
G3P by GPDH. While hepatocytes may use glycerol secreted by adipose during
lipolysis for G3P and TAG synthesis, the activity of glycerol kinase, which
phosphorylates glycerol to G3P, is negligible in adipose tissue, and
glyceroneogenesis is quantitatively the largest contributor of adipocyte G3P
synthesis (79).
In adipocytes, TAG is synthesized by esterification of alcoholic residues of
G3P by a series of enzymes including glycerol-3-phosphate acyltransferase
(GPAT), 1-acylglycerol-3-phosphate acyltransferase (AGPAT), phosphatidic acid
phosphatase, and diacylglycerol acyltransferase (DGAT), found on the smooth
endoplasmic reticulum (15). TAG that is synthesized in adipocytes is stored in
cytosolic lipids droplets. In humans, de novo lipogenesis may account for up to
40% of whole-body lipogenesis (80).
1.1.1.4.4 Lipolysis
When energy demand exceeds energy intake, adipose TAG maybe
hydrolyzed by a process called lipolysis, so that fatty acids and glycerol moieties
may be utilized by other tissues (66) (Figure 1.3). The initial step of TAG
hydrolysis is catalyzed by adipose triglyceride lipase (ATGL) (81). ATGL activity
is regulated transcriptionally (65), by vesicular delivery to lipid droplets (82-84),
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Figure 1.3. Summary of adipocyte lipolysis. AC: adenylate cyclase; ATGL:
adipocyte triglyceride lipase 1; AQP7: aquaglyceroporin 7; CGI-58: comparative
gene identification-58; HSL: hormone sensitive lipase; IRS-1: insulin receptor
substrate-1; MAGL: monoacylglycerol lipase; PDE: phosphodiesterase E; PDK:
pyruvate dehydrogenase kinase; PKA: protein kinase A.
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and by activation by cofactor comparative gene identification-58 (CGI-58) (85). In
the basal state, CGI-58 is associated with perilipin on the surface of the lipid
droplet. In response to a lipolytic stimulus, such as β-adrenergic stimulation by a
catecholamine, perilipin is phosphorylated by protein kinase A (PKA). This
stimulates the dissociation of CGI-58 from perilipin, and its translocation to
ATGL, stimulating ATGL hydrolase activity (86, 87). ATGL is rate-limiting for TAG
hydrolysis (66).
Activation of PKA also results in the phosphorylation of hormone-sensitive
lipase (HSL), the rate-limiting enzyme for diacylglycerol (DAG) hydrolysis (88). In
addition to DAG, HSL can also hydrolyze fatty acids from TAG, monoacylglycerol
(MAG), and cholesterol esters (66), and phosphorylation of HSL at serine 660
(Ser660) regulates HSL enzymatic activity (89). The monocylglycerol that is
produced by the combined activities of ATGL and HSL is hydrolyzed to glycerol
and free fatty acid by the enzyme monoglyceride lipase (MGL). MGL is
expressed ubiquitously, with highest levels of expression found in adipose tissue
and the kidney (66).
Hormone-stimulated lipolysis occurs when a hormone such as a
catecholamine binds to the G-protein-coupled β-adrenergic receptor. This
stimulates adenylate cyclase to produce cyclic-AMP (cAMP), the accumulation of
which activates PKA. PKA phosphorylates perilipin and HSL, and these two
phosphorylation events stimulate the translocation of CGI-58 from perilipin to
ATGL, and the activation and translocation of cytoplasmic HSL to the lipid
droplet, respectively. These phosphorylation and translocation events trigger the
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complete hydrolysis of TAG to three fatty acids and free glycerol. The fatty acids
freed by lipolysis can exit the cell to be used by other tissues, or a portion of
them may be oxidized through a process called β-oxidation in the adipocyte (66).
A small amount of fatty acids hydrolyzed in response to hormone-stimulated
lipolysis, approximately 10-20%, are reesterified as TAG (73, 90-92).
In addition to hormone-stimulated lipolysis, adipocytes also undergo basal
lipolysis. In this state, 30-100% of fatty acids hydrolyzed from the lipid droplet are
reesterified in situ as TAG in a process termed futile TAG/FA cycling (73, 90-92).
This TAG/FA cycling is essential for buffering plasma fatty acid levels and
maintaining tight control over opposing metabolic fluxes (93). This cycling also
plays a role in the synthesis of lipolytic signaling molecules, e.g. fatty acids and
diacylglycerols (73).
1.1.1.4.5 Fatty Acid Oxidation
While the oxidation of fatty acids, or β-oxidation, has been most
extensively studied in oxidative tissue such as skeletal muscle and the liver, βoxidation plays a significant role in white adipocyte metabolism (74). During
differentiation, adipocytes exhibit increased expression of mitochondrial
biogenesis marker PGC1α, and increased mitochondrial oxidative capacity (73).
Prior to entry into the mitochondria for oxidation, fatty acids are activated to form
fatty acyl-CoAs. Following activation, these fatty acyl-CoAs, and are then
transported through the outer mitochondrial membrane by carnitine palmitoyl
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transferase-1 (CPT-1). This transport of fatty acyl-CoAs across the mitochondrial
membrane byCPT-1 is the rate-limiting step of β-oxidation.
The coordinate regulation of lipolysis, β-oxidation, and TAG synthesis are
modulated hormonally, in response to food intake and thus substrate availability
(74). The purpose of lipolysis is to provide energy in the form of fatty acids, for
adipose and other tissues. As glucose is the preferred energy substrate of these
tissues, there is no need for lipolysis or β-oxidation when glucose is present.
Insulin, released from the pancreas in response to feeding, blunts lipolysis in
adipose tissue through Akt-mediated phosphorylation of phosphodiesterase 3B
(PDE3B) (94). Activation of PDE3B reduces the intracellular cAMP pool, and
consequently, PKA-mediated activation of ATGL and HSL. Additionally, indirect
suppression of lipolysis occurs in response to insulin-stimulated glucose uptake
and flux through glycolysis. Adipocytes dispose of a portion of glucose as lactate
(95, 96). Once lactate exits the cell, it can bind to the G protein-coupled GPR81
receptor to inhibit cAMP synthesis, and downstream lipolytic signaling via an
autocrine lactate loop (97). In the presence of glucose, the cytosolic acetyl-CoA
pool that is derived from TCA cycle intermediates is converted to malonyl-CoA by
ACC during de novo lipogenesis. ACC activity is regulated via phosphorylation by
cellular energy sensory AMPK. Malonyl-CoA is a potent inhibitor of CPT-1, and
prevents β-oxidation in a lipogenic state (74). Conversely, when cellular energy
demands exceed substrate availability, AMPK-stimulation of cAMP synthesis by
adenylate cyclase activates PKA, and consequently, stimulates hydrolysis of
TAG (74).
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1.1.1.5 Glucose Metabolism
While skeletal muscle is considered the primary “sink” for glucose
disposal, adipose tissue plays a critical role in regulating glucose homeostasis
(98). A study by Abel et al. demonstrated that relative to control mice, those with
adipose-specific ablation of the GLUT4 glucose transporter exhibit reduced
glucose utilization in adipose tissue and glucose intolerance, as well as impaired
insulin signaling in the liver and skeletal mice (99). Further, glucose homeostasis
in mice lacking GLUT4 in skeletal muscle can be restored by overexpressing
GLUT4 in adipose tissue (100). This beneficial effect of adipose glucose disposal
is dependent on the ability of adipose tissue to utilize glucose for the synthesis of
fatty acids (101).
Glucose may be taken up into the adipocyte via glucose transporter type 1
(GLUT), under basal conditions, or via the GLUT4 glucose transporter in
response to insulin stimulation after a meal (102). While GLUT1 is constitutively
expressed on the plasma membrane of adipocytes, insulin-stimulated GLUT4 is
considered the predominant glucose transporter in adipocytes (74). Under basal
conditions, GLUT4 is stored in small intracellular vesicles (103). In response to
insulin, the PI3K-Akt signaling cascade is triggered, stimulation the exocytosis of
GLUT4-containing vesicles to the cell membrane, and within minutes increasing
flux of glucose into the cell 10- to 30-fold (103, 104).
Once inside the cell, glucose is utilized in multiple cell processes. In
addition to serving as a source of ATP, glucose also serves as a substrate for the

21
synthesis of fatty acids. Additionally, as adipocytes are unable to recycle glycerol
freed by lipolysis, glucose also serves as a substrate for G3P synthesis. It is
estimated that 20-25% of glucose consumed by adipocytes is used for synthesis
of TAG (77).
1.1.2 Changes in Adipose Tissue During Obesity

In a lean individual, adipose tissue works with other tissues to maintain
normal metabolic, inflammatory, and vascular function. In response to
overnutrition, the adipocyte can store excess energy in lipid droplets by
esterifying fatty acids, obtained directly from the diet or synthesized de novo from
glucose, into triacylglycerol. This partitioning of excess energy into adipose tissue
prevent ectopic lipid deposition and lipotoxicity in organs such as the liver, heart,
and skeletal muscle, and preserves normal metabolic functioning in these tissues
(29). However, during the development of obesity, several changes occur in
adipose tissue that disrupt normal functioning.
In response to chronic overnutrition, adipose tissue must expand in order
to accommodate the increased need for energy storage. To do so, the adipose
tissue must increase in cell number, by a process called hyperplasia, or in cell
size, by a process called hypertrophy (74). While both of these processes
contribute to the maintenance of body fat mass, a study by Spalding et al.
demonstrate that changes in cell size, rather than in cell number, underlie
changes in adipose mass during weight loss or gain (105). In this study, it was
found that adipocytes exhibit an annual turnover rate of 10%, regardless of age
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and body mass index. Enlargement of adipocytes stimulates changes in
adipocyte metabolism and secretory profile, and this adipocyte dysfunction plays
a central role in the development of obesity-associated comorbidities, including
insulin resistance, type 2 diabetes, and cardiovascular disease (32).
The expansion of adipose mass triggers a series of inflammatory events.
As the adipocyte expands, a state of hypoxia develops as interstitial oxygen
tension decreases within the adipose tissue (106, 107). This stimulates
stabilization of HIF1α, which is rapidly degraded under normoxic conditions, and
upregulation of genes containing HIF1α response elements, such as those
required for angiogenesis (108). In lean individuals, macrophages found in
adipose tissue express markers of the M2, or alternatively activated, state. M2
macrophages are characterized by secretion of anti-inflammatory cytokines, such
as interleukin-10 (IL-10) (31). During obesity, recruitment and accumulation of
M1, or classically activated, macrophages occurs. M1 macrophages
characterized by increased production of pro-inflammatory cytokines tumor
necrosis factor alpha (TNFα) and interleukin-6 (IL-6), which promote insulin
resistance and low-grade systemic inflammation (18, 31).
As the white adipose tissue further expands, necrosis occurs, stimulating
the development of “crown-like structures” composed of the dead adipocyte
surrounded by macrophages (109). The rate of cell death is positively correlated
with adipocyte size in mice and in humans, and is increased up to 30-fold in
obese compared to lean individuals (110). This inflammatory response is
implicated in the metabolic disturbances associated with obesity.
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In addition to elevated local and systemic inflammation, dysregulation of
lipolysis occurs during the development of obesity (111). In obese and insulinresistant individuals, catecholamine-induced lipolysis is blunted in subcutaneous
adipose tissue, but increased in visceral adipose depots (112, 113). Further,
basal (unstimulated) lipolysis is increased in obese compared to individuals (112,
114), and this uncontrolled release of fatty acids is closely associated with
obesity-associated insulin resistance, independent of age or BMI (115). These
obesity-induced metabolic consequences have a devastating impact on overall
health and quality of life. The need to identify safe, effective measures by which
the burden of obesity can be prevented and reversed is critical. This dissertation
discusses the potential impact of vitamin D on obesity and obesity-associated
metabolic disorders.
1.2

Role of Vitamin D in Human Health

1.2.1 Sources of Vitamin D

Vitamin D is a 9, 10 secosteroid that was first discovered by Dr. E.V.
McCollum in 1922 as the factor present in cod liver oil that cured rickets in
experimental beagles (116). Of the many forms of vitamin D that have been
identified, only vitamins D2 (ergocalciferol; fungal origin) and D3 (cholecalciferol;
animal origin) (Figure 1.4) are relevant to human health (117). Vitamin D3 is a
biologically inert prohormone made endogenously from 7-dehydrocholesterol in
the skin upon exposure to ultraviolet light (Figure 1.5) (118). Upon irradiation,
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Vitamin D2
Figure 1.4. Chemical structures of vitamins D2 and D3.

Vitamin D3
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Figure 1.5. Vitamin D3 biosynthesis and metabolism.
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7-dehydrocholesterol is converted to pre-vitamin D3 which is then converted to
vitamin D3 upon the temperature-sensitive rearrangement of three double bonds
(119). Modest amounts of vitamin D3 may also be obtained in the diet through
consumption of vitamin D-fortified dairy products and fatty fish. While reports of
superiority of vitamin D3 have been made when supplemented at high doses
(120), at low doses, vitamins D2 and D3 are nutritionally equivalent (121).
1.2.1.1 Vitamin D Metabolism
Whether obtained through the diet or synthesized endogenously, vitamin
D circulates in the blood bound to vitamin D binding protein (DBP). While vitamin
D itself does not have biological activity, it becomes active upon hydroxylation at
two distinct sites. In the liver, vitamin D is hydroxylated C-25 by the 25hydroxylase CYP2R1 to produce 25-hydroxyvitamin D (25(OH)D). 25hydroxylation in the liver is not a highly regulated step (122), and serum
concentrations of 25(OH)D are a universally accepted biomarker of vitamin D
status (123-125).
Though 25(OH)D is the major circulating metabolite of vitamin D,
conversion to the active metabolite 1,25-dihydroxyvitamin D (1α,25(OH)2D;
calcitriol) requires an additional hydroxylation at C-1, which occurs in the kidney.
When DBP-bound 25(OH)D reaches the kidney, it is filtered by the glomerulus.
Megalin, a transmembrane protein found in tubular epithelial cells, acts as a cell
surface receptor for DPB, and catalyzes the uptake of 25(OH)D by endocytic
internalization (126). In the proximal renal tubule, conversion of 25(OH)D to
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1α,25(OH)2D is mediated by the renal 1α-hydroxylase CYP27B1. This enzyme is
under tight regulation in the kidney; it is activated by serum PTH and suppressed
by 1,25(OH)2D, calcium and phosphorus (127, 128). While the kidney is the main
site of 25(OH)D activation under periods of low calcium or low phosphorus
stress, CYP27B1 expression and 1α-hydroxylase activity have now been
identified in several extra-renal tissues, including skin, colon, lung, bone,
prostate, intestine, pancreatic islets, vasculature, liver, brain, muscle and adipose
tissue (129-131). The extra-renal 1α-hydroxylase is not regulated by PTH (132,
133), suggesting that elevated 25(OH)D status may lead to local production of
1α,25(OH)2D independent of calcium status to yield autocrine and paracrine
responses. In response to elevated circulating 1,25(OH)2D levels, the renal
CYP27B1 hydroxylates 1,25(OH)2D, and also 25(OH)2D, at C-24 to signal for its
degradation and excretion (134, 135). While concentrations vary widely based on
dietary intake, studies have demonstrated that both vitamin D and 25(OH)D may
be found in adipose tissue, skeletal muscle and liver, though the largest pool of
25(OH)D is found in serum (125, 136).
1.2.1.2 Classical Signaling of 1,25(OH)2D through the Vitamin D Receptor
Like other steroid hormones, 1,25(OH)2D functions through a nuclear
receptor, in this case, the vitamin D receptor (VDR). The VDR belongs to the
class II of steroid receptors, and is closely related to the thyroid hormone and
retinoic acid receptors (128, 137), and is evolutionarily conserved among
mammals, birds, and fish (138). Like other nuclear receptors, the VDR has a
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ligand-binding domain called the E-domain, a DNA-binding domain called the Cdomain, and an activating domain called the F-domain (116). The human VDR
protein contains 427 amino acids, and acts by binding to vitamin D response
elements (VDREs), which are typically found within 1 kilobase of the transcription
start site of the vitamin D target gene. The VDREs are repeat sequences of 6
nucleotides separated by 3 nonspecific bases (116).
Upon entry into the cell, 1,25(OH)2D binds to the VDR, causing a
conformational change in the VDR that allows it to interact and form a
heterodimer with the retinoid X receptor (RXR). This heterodimer binds to the
VDRE to regulate transcription of vitamin D target genes (139). Binding of the
VDR-RXR heterodimer to VDREs stimulates recruitment of transcriptional
coactivators such as p160 coactivator and steroid receptor activator (SRC) (119).
Once this complex forms, transcription is either stimulated or repressed,
depending on the gene (116). 1,25(OH)2D regulation of transcriptional events
through the VDR is responsible for the regulation of calcium homeostasis (137,
140). In addition to its identification in tissues controlling calcium homeostasis,
the VDR has now been identified in virtually all other tissues (141-143), as well
as a variety of cancer cells including those from the breast, colon, and prostate
(144-147). This broad distribution of VDR supports the existence of extraskeletal
effects for 1,25(OH)2D (139, 148, 149).
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1.2.1.3 Rapid Signaling through the Membrane Vitamin D Receptor
Though the most well-established mechanisms of calcitriol action are through the
nuclear VDR to modulate gene expression, strong evidence exists proving nongenomic actions of 1,25(OH)2D as well. First documentation of rapid 1,25(OH)2D
action was in a 1984 study by Nemere (150), in which addition of 120 pM
1,25(OH)2D to perfused deuodena of normal, vitamin D-replete chicks resulted in
a significant increase of 45Ca transport from the lumen to the vascular effluent
within 14 minutes. This rapid response, within minutes, contrasts with genomic
responses which may take hours to several days, and can be blocked by
inhibitors of transcription and translation. Since this discovery, many studies
have emerged supporting the existence of non-genomic actions of calcitriol in
regulation of calcium transport in several cell types, including hepatocytes, the
promyelocytic HC-60 cell line, renal tissue and mammary glands, among others
(151).
Investigation of the mechanisms of 1,25(OH)2D-stimulation of rapid
signaling events have revealed a novel role for the vitamin D receptor. Many
ligand structure-function studies have been done to elucidate rapid responses of
1,25(OH)2D bound to the classic VDR, including rapid stimulation of: calcium
absorption in chick enterocytes (152, 153), insulin secretion from rat pancreatic β
cells (89), rate of human endothelial cell migration (154), and MAPK and
PI3K/Akt signaling cascades to regulate proliferation and differentiation in
skeletal muscle (155-157). In these studies, the 1α,25(OH)2D agonist could be
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inhibited by the rapid response antagonist 1β,25(OH)2D, but not by the genomic
response antagonist (23S)-25-dehydro-1α-OH-D3-26,23-lactone (158). Further,
these rapid responses were also induced by 6-s-cis locked 1α,25(OH)2lumisterol, which binds to the VDR (153). Together, these data demonstrate that
the rapid responses initiated by 1,25(OH)2D do in fact occur through the classical
VDR, but also that rapid responses require a different ligand structure (6-s-cis)
than that required for a 1,25(OH)2D-induced genomic response (6-s-trans) (159).
1.2.1.4 A Non-VDR Membrane-Associated Binding Protein is Involved in Rapid
1,25(OH)2D Signaling
Though there are a data to support a direct role for the VDR in nongenomic 1,25(OH)2D actions, initial studies in enterocytes, chondrocytes, and
osteoblasts suggested that a different 1,25(OH)2D binding protein controlled rapid
calcitriol-induced signal transduction pathways. Indirect evidence for a putative
membrane receptor for 1,25(OH)2D was obtained during the initial discovery of
calcitriol rapid signaling in the intestine. In these studies, treatment of the
basolateral membrane with exogenous 1,25(OH)2D rapidly enhanced calcium
transport, whereas exposure of the brush border failed to have this effect (150).
This suggested that 1,25(OH)2D receptor exists on the basolateral membrane.
Isolation and full characterization and identification of this basolateral
membrane receptor in chick intestinal epithelial cells was achieved several years
later, and was termed the 1,25(OH)2D-membrane-associated, rapid-response
steroid-binding (MARRS) protein (160). The transcript for the 1,25(OH)2D-
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MARRS includes a 5’-unstranslated region, a signal peptide, no transmembrane
domain and two thioredoxin motifs. Analysis of the cloned chicken cDNA for the
1,25(OH)2D-MARRS revealed that it is identical to the multifunctional protein
ERp57 protein (also called p57/GRp58/Pdia3). The ERp57 is a thiol:protein
disulphide oxidoreductase, and is a member of the protein disulfide isomerase
(PDI) family (161). First identified as a luminal chaperone protein of the
endoplasmic reticulum to facilitate oxidative folding of glycoproteins, ERp57
exists also in the cytoplasm and nucleus, and functions as a scaffolding protein
on the cell surface (162).
1,25(OH)2D-MARRS mediates several 1,25(OH)2D-induced effects in
various cell types, including rapid (seconds to minutes) phosphate (163, 164) and
calcium (165, 166) uptake in intestinal epithelial cells and perfused duodena,
modulation of growth inhibitory activity of 1,25(OH)2D in breast cancer cells
(167), regulation of growth plate physiology in chondrocytes and matrix vesicle
models (168), and initiation of 1,25(OH)2D signaling pathways in osteoblast
differentiation (169).
1.2.1.5 Classical Roles of Vitamin D in Calcium Metabolism and Bone Health
Historically, the chief functions of vitamin D are those related to bone
mineralization (170). It is well established that the rachitic skeleton can be
mineralized by infusion of calcium and phosphorus to raise their serum levels into
normal ranges (171), indicating that a direct role for vitamin D in bone
mineralization is not likely. However, vitamin D does contribute to bone health by
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maintaining serum calcium and phosphorus concentrations within ranges
necessary to support bone mineralization. The control of serum calcium occurs
through events occurring at a three-tissue axis of bone, intestine, and kidney.
When dietary calcium is insufficient, vitamin D is converted to its hormonal form
1,25(OH)2D, that acts on the enterocyte to activate active transport of calcium
and also phosphorus, on the osteoclast to mediate bone resorption, and on the
kidney to increase renal reabsorption of calcium in the distal tubule. All of these
events contribute to maintaining plasma calcium concentrations within a very
narrow range (116, 123).
1.2.1.6 Extraskeletal Functions of Vitamin D
In addition to those related to maintaining serum calcium and bone
mineralization, several extraskeletal functions of vitamin D have been identified.
Meta-analysis of randomized clinical trials have demonstrated that vitamin D
status is inversely correlated with cancer-related mortality, suggesting that
vitamin D may act to inhibit the progression of certain cancers (119). In particular,
evidence exists demonstrating vitamin D inhibition of prostate, breast, and colon
cancer progression. Additionally, observational studies demonstrate an inverse
relationship between vitamin D status and risk of cardiovascular disease, and in
vitro studies have demonstrated 1,25(OH)2D regulation of cell proliferation and
differentiation, as well as regulation of immune function (119, 172).
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1.2.1.7 Recommendations for Dietary Intake of Vitamin D
Current recommendations for serum 25(OH)D are made based on the
impact that vitamin D has on skeletal health (173) (Table 1.1). Serum 25(OH)D
levels of 50 nmol/L (20 ng/mL) are considered adequate to normalize bone and
calcium metabolism in at least 97.5% of the population. The Institute of Medicine
(IOM) defines “insufficiency” as any serum 25(OH)D concentration < 50 nmol/L,
and “deficiency” as levels of serum 25(OH)D levels at which bone health is
compromised, i.e. <30 nmol/L (12 ng/mL) (173). The Recommended Dietary
Allowances (RDAs) for vitamin D, the average daily level of intake sufficient to
meet vitamin D requirements of 97%-98% of healthy individuals, are listed in
Table 1.2 (121).
While rare, it is possible to achieve vitamin D toxicity, particularly with
long-term use of extreme vitamin D supplementation. Symptoms of vitamin D
toxicity include anorexia leading to weight loss, heart arrhythmias, and polyuria.
In more serious cases, vitamin D toxicity may lead to elevated blood calcium
levels, resulting in vascular and tissue calcification, and consequently, cardiac,
renal, and vascular damage (121). The occurrence of vitamin D toxicity is rare,
however, and it is not possible to achieve toxicity from foods or sunlight exposure
(124).The Tolerable Upper Intake Levels (ULs) for vitamin D, or the highest
average daily intake level likely to pose no risk of adverse health outcomes, are
listed in Table 1.3 (121).
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Table 1.1 Recommended serum 25-hydroxyvitamin D [25(OH)D] concentrations
nmol/L*

ng/mL

<30

<12

30 to <50

12 to <20

Generally considered adequate for bone
health in healthy individuals

≥50

≥20

Generally considered adequate for bone
health in healthy individuals

>125
>50
*1 nmol/L = 0.4 ng/mL

Health Outcome
Vitamin D deficiency, leading to rickets and
osteomalacia in children and adults

Risk of adverse effects is increased when
serum 25(OH)D reaches >125 nmol/L
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Table 1.2 Recommended Dietary Allowances (RDAs) for vitamin D
Age
0-12 months*

Male
400 IU
(10 µg)
1-13 years
600 IU
(15 µg)
14-18 years
600 IU
(15 µg)
19-50 years
600 IU
(15 µg)
51-70 years
600 IU
(15 µg)
>70 years
800 IU
(20 µg)
*Adequate Intake (AI)

Female
400 IU
(10 µg)
600 IU
(15 µg)
600 IU
(15 µg)
600 IU
(15 µg)
600 IU
(15 µg)
800 IU
(20 µg)

Pregnancy

Lactation

600 IU
(15 µg)
600 IU
(15 µg)

600 IU
(15 µg)
600 IU
(15 µg)
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Table 1.3 Tolerable Upper Intake Levels (ULs) for vitamin D
Age
0-6 months
7-12 months
1-3 years
4-8 years
≥9 years

Male
1,000 IU
(25 µg)
1,500 IU
(38 µg)
2,500 IU
(63 µg)
3,000 IU
(75 µg)
4,000 IU
(100 µg)

Female
1,000 IU
(25 µg)
1,500 IU
(38 µg)
2,500 IU
(63 µg)
3,000 IU
(75 µg)
4,000 IU
(100 µg)

Pregnancy

Lactation

4,000 IU
(100 µg)

4,000 IU
(100 µg)
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However, the above described definitions of vitamin D adequacy,
insufficiency, and deficiency are not universally used, and some strongly oppose
these current IOM recommendations (174). Recent evidence from some studies
evaluating thresholds for serum 25(OH)D concentrations in relation to bone as
well as several extraskeletal endpoints suggest that the most advantageous
serum 25(OH)D concentrations begin at 75 nmol/L (30 ng/mL), and are optimal
between 90 and 100 nmol/L (36-40 ng/mL) (175). Whether there is sufficient
evidence to conclude that optimal serum 25(OH)D levels are higher than current
IOM levels remains a matter of debate.
The prevalence of vitamin D deficiency is widespread, both in the U.S.
(176) and worldwide (177). It is estimated that approximately one-third of the
U.S. population is vitamin D deficient or insufficient, with certain ethnic groups at
particularly high risk of low vitamin D status, including non-Hispanic blacks
(>70%) and Hispanics/Mexicans (>40%) (178). This raises concern, as mounting
evidence demonstrates the existence of many biological functions of vitamin D, in
addition to the classical functions of vitamin D related to regulation of calcium
and phosphate homeostasis and bone metabolism.
Additionally, vitamin D status has been implicated in the development of
obesity-associated metabolic disorders (179). Human cross-sectional studies
demonstrate that vitamin D deficiency is association with hyperglycemia (180,
181), hyperinsulinemia (182), reduced pancreatic beta-cell function (183), and
measures of insulin resistance (183). Further, early studies utilizing vitamin Ddeficient rats found that pancreatic insulin secretion was impaired compared to
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that of vitamin D-replete rats (184, 185). The relationship between vitamin D
supplementation and glycemic control remains controversial. In vitro studies
demonstrate that 1,25(OH)2D enhances insulin sensitivity in skeletal muscle
(186), a major contributor to global insulin sensitivity. However, recent metaanalyses of randomized controlled trials designed to assess the impact of vitamin
D supplementation on insulin sensitivity failed to show a positive effect of vitamin
D supplementation on homeostatic model assessment of insulin resistance
(HOMA-IR), or on 2-hour plasma glucose following an oral glucose tolerance test
(OGTT) (187, 188). One meta-analysis did find small yet statistically significant
reductions in fasting blood glucose and HbA1c levels in individuals with
prediabetes who received vitamin D supplementation (187). The relationship
between vitamin D and insulin sensitivity remains incompletely understood
1.3

Vitamin D Plays a Role in Adipose Tissue Physiology

1.3.1 Relationship between Vitamin D Status and Obesity

The inverse relationship between vitamin D status and adiposity is wellestablished: serum 25-hydrovyvitamin D [25(OH)D] levels are inversely
correlated with measures of adiposity including fat mass, body mass index (BMI),
and waist circumference (189-194). Several hypotheses have been studied
regarding the nature of this relationship. One such hypothesis is that vitamin D
deficiency plays a causative role in the development of obesity, which resulted in
the execution of studies designed to determine the impact of vitamin D
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supplementation on weight loss and obesity-associated comorbidities. The
existing evidence however does not support this causal relationship (179).
Analysis of intervention studies having a duration of 1 year and achieving serum
25(OH)D of >85 nmol/L found no significant changes in BMI (195, 196).
Consistent with these findings, participants given 2,000 IU/day vitamin D in a
short randomized controlled trial experienced significant increases in serum
25(OH)D and 1,25(OH)2D with no changes in energy expenditure or adipose
tissue gene expression (197). Taken together, these studies indicate that vitamin
D supplementation alone is not an effective means by which to induce weight
loss.
The inverse relationship between vitamin D deficiency and adiposity may
be attributed to lifestyle factors that promote both of these conditions. Examples
would include a diet poor in vitamin D, and little outdoor exercise (and thus
reduced solar ultraviolet radiation and endogenous production of vitamin D) (191,
198). Alternatively, it has been postulated that obese individuals may have
reduced circulating 25(OH)D due to sequestration of vitamin D and its
metabolites in adipose tissue. The evidence is most compelling for the latter of
these hypotheses.
1.3.1.1 Sequestration of Vitamin D in Adipose Tissue
It has been established that adipose tissue is a storage site of vitamin D
(199-201). In rats, adipose tissue accounts or the majority of vitamin D storage,
half stored as unmetabolized vitamin D and the other half stored as vitamin D
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metabolites, esters, and other unidentified compounds (200). The inverse
relationship between vitamin D status and adiposity may be explained by
sequestration of the nutrient in adipose tissue. An investigation led by Wortsman
et al. demonstrated that the increase in serum vitamin D3 following whole-body
irradiation was 57% lower in obese than in age-matched lean controls (202). This
occurred despite no significant difference in the cutaneous vitamin D precursor 7dehydrocholesterol between these two groups, and no difference in the
conversion of 7-dehydrocholesterol to previtamin D3. Further, an inverse
correlation was found between BMI and peak serum vitamin D2 concentrations
following oral administration of 50,000 IU vitamin D2, suggesting that obesityassociated vitamin D deficiency is likely due to its reduced bioavailability resulting
from sequestration in adipose tissue depots (202). A study by Vimaleswaran et
al. arrived at a similar conclusion upon employing a Mendelian randomization
approach for determining directionality and causation of the association between
vitamin D status and BMI (203). The results from this study reveal that a higher
BMI was causally linked to reduced serum 25(OH)D levels, but the findings did
not suggest that raising serum 25(OH)D levels will have a BMI lowering effect.
While these studies clearly demonstrate that excessive adiposity underlies
obesity-associated vitamin D deficiency, it is not yet known whether direct action
of vitamin D on adipose tissue plays a role in this relationship.
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1.3.1.2 Role of 1,25(OH)2D and the VDR in Adipogenesis
Expansion of adipose tissue occurs as a result of the enlargement of
adipocyte size (hypertrophy) and an increase in adipocyte number (hyperplasia).
Both of these processes occur during adipocyte differentiation, in a process
called adipogenesis. The vitamin D receptor, a nuclear receptor that
heterodimerizes with RXR, is expressed in adipose tissue and is acutely
upregulated during adipogenesis in vitro (204). Many in vitro studies using
established cell lines have demonstrated 1,25(OH)2D regulation of preadipocyte
differentiation.
In mouse 3T3-L1 preadipocytes, differentiation is inhibited by 1,25(OH)2D
via downregulation of C/EBPα and PPARγ expression and sequestration of RXR,
resulting in downregulation of C/EBPβ (205-208). Further, upregulation of
C/EBPβ corepressor eight twenty-one (ETO) by 1,25(OH)2D further reduces
C/EBPβ activity and inhibits adipogenesis. More recently, Lee et al. demonstrate
that in 3T3-L1 preadipocytes, 1,25(OH)2D promotes maintenance of WNT10B
and nuclear β-catenin expression, suppressing PPARγ activity and preserving
the preadipocyte phenotype (207). Additionally, it has been demonstrated that
VDR knockdown inhibits adipogenesis in 3T3-L1 preadipocytes (206), and that
VDR null mice exhibit an extremely lean phenotype with resistance to diet
induced obesity (209-211).
However, 1,25(OH)2D regulation of preadipocyte differentiation appears to
be species-dependent. In porcine mesenchymal stem cells,1,25(OH)2D
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stimulates differentiation towards an adipocyte phenotype by stimulating PPARγ,
lipoprotein lipase (LPL), and aP2 expression (212). In human subcutaneous
preadipocytes, differentiation is stimulated by 1,25(OH)2D, resulting in increased
expression of FABP4 and LPL (213). Narvaez et al. conducted genomic profiling
of primary cultures of human adipose-derived mesenchymal progenitor cells to
define the role of 1,25(OH)2D and its VDR in adipogenesis, and found that
1,25(OH)2D promoted lipid accumulation and enhanced expression of FABP4,
FASN, and PPARγ (214). The discrepancies observed between studies utilizing
human versus mouse 3T3-L1 preadipocytes may be due to methodological
differences, or due to differences in the roles of adipose tissue in energy balance
between the two species. Regardless, 1,25(OH)2D appears to play a multifaceted
role in the regulation of adipose tissue physiology.
1.3.1.3 Regulation of Inflammation by 1,25(OH)2D
During obesity, expansion of adipose tissue results in insufficient blood
flow to the hypertrophic tissue, stimulating hypoxia, macrophage infiltration, and
inflammation. In this state, secretion of adiponectin and other anti-inflammatory
adipokines are reduced, while secretion of pro-inflammatory cytokines such as
interleukin-6 (IL-6), TNFα, resistin, and MCP-1 are increased (215). While vitamin
D regulation of adipose tissue inflammation remains incompletely defined,
several in vitro studies have demonstrated that 1,25(OH)2D does act at several
levels to modulate this system. Studies by Zemel et al. utilizing 3T3-L1 and
human adipocytes have found that 1,25(OH)2D exerts a pro-inflammatory effect,
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inhibiting anti-inflammatory cytokine expression while stimulating expression of
pro-inflammatory cytokines. In these studies, treatment of adipocytes with
1,25(OH)2D increased expression of TNFα, IL-6, IL-8, macrophage colonystimulating factor (M-CSF), and macrophage inflammatory factor (MIF) (216218). Expression of M-CSF and MIF were ameliorated by calcium-channel
antagonism with nifedipine, indicating that 1,25(OH)2D operates via a calciumdependent mechanism (218).
However, not all studies have revealed consistent findings. In contrast to
the pro-inflammatory properties identified by Zemel and colleagues, several
recent investigations utilizing human preadipocytes and mature human
adipocytes have identified an anti-inflammatory role of 1,25(OH)2D in adipocyte
physiology. An investigation of the effects of high vitamin D and calcium intake in
a Western diet on energy metabolism and inflammation revealed that mice on a
Western diet, as expected, experienced reduced energy expenditure and excess
fat accumulation compared to mice fed a control diet. Interestingly, mice fed a
Western diet plus vitamin D and calcium experienced significantly higher fat
deposition in AT and in the liver compared to mice fed a Western diet low in
these nutrients. However, the Western diet-induced increase in circulating
inflammatory markers IL-1β and MCP-1 were ameliorated by high vitamin D and
calcium (219). In vitro studies have yielded similar findings. Investigations by
Marcotorchino et al. found reductions in protein and mRNA expression of TNFα,
IL-6, MCP-1, and IL-1β with 1,25(OH)2D treatment of human and 3T3-L1
adipocytes (220). In human preadipocytes, 1,25(OH)2D reduced MCP-1, IL-6 and
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IL-8 secretion under basal and proinflammatory conditions (221). These and
additional studies provide evidence to support that the anti-inflammatory effects
of 1,25(OH)2D on adipose tissue are via inhibition of the NFκB signaling pathway
(220-223).
Though many studies do demonstrate vitamin D regulation of adipose
tissue inflammation in vitro and in vivo, this system does not appear to be as
highly regulated by vitamin D in humans. Clinical intervention studies designed to
examine the effect of vitamin D supplementation on markers of inflammation
have failed to see improvements in systemic and AT inflammation. A doubleblind intervention study of 52 obese (BMI > 30 kg/m2), vitamin D-deficient
(plasma 25(OH)D <50 nM) individuals failed to see an effect of 26 weeks of
7,000 IU vitamin D3/day on any of the examined circulating inflammatory
markers, including Hs-CRP, IL-6, MCP-1, adiponectin, leptin, MMP-9, and PAI-1,
despite achieving plasma 25(OH)D concentrations of 110.2 ± 21.2 nM by the end
of the intervention period (224). Further analysis by the same group also
confirmed no change in AT markers of inflammation in these subjects following
oral vitamin D supplementation (225). While 1,25(OH)2D appears to have largely
anti-inflammatory effects in vitro and in vivo, more studies are needed in order to
determine the physiological relevance of these findings in humans.
1.3.1.4 Vitamin D Regulation of Energy Metabolism
Vitamin D, or more specifically the vitamin D receptor, also appears to
modulate energy metabolism. Recent investigations utilizing VDR knockout
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(VDR-/-) mice have revealed that ablation of the VDR leads to reduced body
weight, hyperphagia with resistance to diet-induced obesity, hypolipidemia, and
hypoleptinemia (209-211). VDR null mice also exhibit increased UCP-1
expression, energy expenditure, oxygen consumption and basal metabolism
compared to wild-type (WT) mice (210). These findings of increased energy
expenditure and resistance of VDR-null mice to diet-induced obesity has led to
investigations of the role of the VDR in adipocyte energy and lipid metabolism
(210, 226).
An additional study by Wong et al. utilized the aP2 gene promoter to target
the expression of human (h) VDR in adipocytes in mice (227). In contrast to the
VDR-null mice, aP2-hVDR Tg mice exhibited reduced locomotive activity and
energy expenditure, and increased accumulation of fat mass compared to WT
mice. Adipose tissue of the transgenic mice exhibited reduced fatty acid βoxidation and expression of genes involved in the regulation of fatty acid
transport, thermogenesis, and lipolysis. Collectively, these findings suggest a role
for VDR regulation of energy metabolism in adipocytes, and it has been
speculated that vitamin D storage within adipose tissue increases local vitamin D
concentration and thus activation of the VDR, negatively affecting energy
expenditure and exacerbating fat mass accumulation. However, the applicability
of these findings in humans has yet to be determined.
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1.3.1.5 1,25(OH)2D May Regulate Adipocyte Lipid Metabolism
While limited data exist regarding direct effects of 1,25(OH)2D on
adipocyte lipid metabolism, the hormone may modulate lipid metabolism
indirectly via its relationship with calcium metabolism. It was previously noted that
a high calcium diet suppressed renal 1,25(OH)2D production in aP2-agouti
transgenic mice, leading to decreased intracellular Ca2+ ([Ca2+]i), stimulation of
lipolysis, inhibition of lipogenesis, and reduced adiposity (228, 229). To
determine whether this modulation of adipocyte lipid metabolism is a direct effect
of inhibition of 1,25(OH)2D-induced [Ca2+]i, differentiated adipocytes from a
human adipocyte cell line and primary-cultured human adipocytes were treated
with 1,25(OH)2D for 48 hours, and intracellular [Ca2+]i, rate of lipolysis, and
expression and activities of lipid metabolism enzymes examined. Adipocytes
exhibited a 1,25(OH)2D dose-responsive (1-50 nM) increase in [Ca2+]i (P<0.01),
a 50-100% increase in FAS expression and activity (P<0.02), a 61% increase in
GPDH activity (P<0.01), and 80% inhibition of isoproterenol-stimulated lipolysis
(P<0.001) (230). Using an agonist (1α,25-dihydroxylumisterol3) and antagonist
(1β,25-(OH)2D3) of the putative membrane vitamin D receptor (mVDR), the
authors demonstrated that 1,25(OH)2D elicits a nongenomic response in
adipocytes, resulting in stimulation of [Ca2+]i and corresponding modulation of
lipid metabolism. Further study by the same group demonstrated that treatment
of human adipocytes for 48 hrs with 1 nM 1,25(OH)2D simulated a 50% reduction
in UCP2 mRNA and protein levels (P<0.002), and blocked isoproterenol- or fatty
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acid-stimulated increases in UCP2 expression (231). Collectively, the authors
conclude that the anti-obesity effects of dietary calcium are, at least in part, via
inhibition of 1,25(OH)2D production.
Some investigations have been conducted to examine this relationship
between calcium, vitamin D, and lipolysis in humans. Four studies have reported
that obese individuals have high serum concentrations of 1,25(OH)2D compared
to non-obese individuals (189, 190, 232, 233), and it has been suggested that
1,25(OH)2D, via its ability to increase intracellular Ca2+ concentrations particularly
in adipocytes, may exacerbate fat mass accumulation in those predisposed to
obesity (228, 234). However, these studies employed very small cohorts of
obese subjects, all of whom appeared to have been Caucasian. To address this,
a subsequent study was conducted by Parikh et al., in which the relationships
between calciotropic hormones and body adiposity were examined in 154 healthy
obese (BMI = 37.3 ± 5.8 kg/m2) and 148 healthy non-obese (BMI 25.6 ± 2.9
kg/m2) individuals of Caucasian (62.9%), African-American (27.8%), and other
(9.3%) race/ethnicities (235). In both Caucasian and African-American adults, it
was found that serum 1,25(OH)2D was significantly lower in obese subjects
relative to nonobese subjects (105.7 ± 41.1 vs. 124.8 ± 36.7pmol/liter; P <
0.0001). Serum intact PTH was positively correlated with both BMI (r = 0.42;
P<0.0001) and body fat mass (r = 0.37; P < 0.0001), while serum 25(OH)D and
1,25(OH)2D were negatively correlated with BMI (25(OH)D: r = 0.4, P < 0.0001;
1,25(OH)2D: r = 0.26; P < 0.0001) and body fat mass (25(OH)D: r = 0.41; P <
0.0001; 1,25(OH)2D: r = 0.25; P < 0.0001). These relationships existed
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independent of age, sex, or race, and do not support the hypothesis that
1,25(OH)2D exacerbates fat mass accumulation in the obese.
While the effect of vitamin D on adipocyte differentiation, inflammation,
and energy metabolism have been studied, the impact of vitamin D on lipid
metabolism in adipocytes that have completed terminal differentiation is
incompletely understood. The studies described within aim to address this
knowledge gap.
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CHAPTER 2. MATERIALS AND METHODS

2.1

Chemicals and Reagents

Dulbecco's Modification of Eagle's Medium (DMEM) was obtained from
Corning (Manassas, VA). Bovine calf serum was obtained from Thermo Fisher
Scientific (Pittsburgh, PA). 1,25(OH)2D was obtained from Enzo Life Sciences
(East Farmingdale, NY). Fetal bovine serum, trypsin, and penicillin/streptomycin
were obtained from Life Technologies, Gibco-BRL (Rockville, MD). Protease
inhibitors cocktail, essentially fatty acid-free bovine serum albumin (FA-Free
BSA),trypan blue solution (0.4%), insulin (bovine), dexamethasone, 3-Isobutyl-1methylxanthine were obtained from Sigma-Aldrich (St. Louis, MO). Rosiglitazone
was obtained from Cayman Chemical (Ann Arbor, MI). PKA inhibitor H-89
dihydrochloride was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Antibodies for HSL, phospho-HSL (Ser565 and Ser660), perilipin, and
GAPDH were purchased from Cell Signaling Technology, Inc. (Danvers, MA).
2.2

Cell Culture

3T3-L1 fibroblasts were obtained from American Type Culture Collection
(ATCC CL-173; Manassas, VA), and cultured in DMEM containing 10% (vol:vol)
FCS with 100 U/mL penicillin and 100 µg/mL streptomycin at 37⁰C and 5% CO2.
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Adipocyte differentiation was initiated 2 days post-confluence (referred to as day
0) using DMEMcontaining 10% (vol:vol) FBS, antibiotics, and a differentiation
cocktail consisting of 1.0 µg/mL insulin, 0.5 mM isobutylmethylxanthine, 1.0 µM
dexamethasone, and 2.0 µM rosiglitazone (236). On day 2, this medium was
replaced with DMEM containing 10% FBS, antibiotics, and 1.0 µg/mL insulin.
Beginning on day 4, cells were maintained in DMEM containing 10% (vol:vol)
FCS and antibiotics, and the medium was changed every 2 days. Adipocytes
were differentiated for 9 days, to allow for complete differentiation, and lipid
accumulation (Figure 2.1). On day 9, 1,25(OH)2D (10 nM) was delivered to cells
for the times indicated in 100% ethanol at a final ethanol concentration of <0.1%.
For experiments lasting longer than 24 hours, cell medium containing
1,25(OH)2D or vehicle was refreshed every 24 hours. Cell viability was assessed
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and
trypan blue exclusion assays, according to manufacturer protocol.
2.3

Triacylglycerol Quantification

Following 1,25(OH)2D treatment, neutral lipids were extracted using a 3:1
hexane:isopropanol solution, and dried under nitrogen gas. Neutral lipids were
resuspended in chloroform containing 1% (vol:vol) triton X-100. Lipids were again
dried under nitrogen gas, and resuspended in dH2O containing 2% (vol:vol) triton
X-100. Triacylglycerol accumulation was assessed using a spectrophotometric
assay kit from Wako Diagnostics (Richmond, VA), according to manufacturer
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Figure 2.1. BODIPY staining of neutral lipids in differentiated 3T3-L1 adipocytes.
Differentiated adipocytes were fixed with paraformaldehyde, and stained with
BODIPY 493/503 (green) and DAPI (blue) to stain neutral lipids and nuclei,
respectively. Imaging was performed using a Nikon A1R_MP confocal
microscope.
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protocol. Results are normalized against quantity of protein per well, which was
quantified using the bicinchoninic acid assay (BCA assay: Pierce; Rockford, IL).
2.4

Glycerol, Non-Esterified Fatty Acid, and Lactate Release

Spent medium samples were collected after 24 hours of treatment and
used for analysis of glycerol, NEFA, and lactate. Glycerol and NEFA were
quantified using spectrophotometric assay kits from Sigma-Aldrich (St. Louis,
MO) and Wako Diagnostics (Richmond, VA), respectively. For PKA inhibition
studies, following 48 hours of treatment with 1,25(OH)2D (10 nM) or vehicle, cells
were pre-treated for two hours with PKA inhibitor H-89 (75 µM), with 1,25(OH)2D
as indicated. Following pre-treatment, the medium was replaced with serum-free
DMEM containing vehicle or 1,25(OH)2D and H-89 as indicated for an additional
4 hours, after which the medium was collected for determination of glycerol
release. Lactate secretion was determined using a spectrophotometric method
based on the principle that in the presence of NAD+, lactate in spent media
samples can be converted to pyruvate by lactate dehydrogenase. Hydrazine is
added to destroy the pyruvate produced, allowing the reaction to run to the
complete oxidation of all lactate molecules. The amount of NADH formed by the
reaction is proportionate to the amount of lactate in the media, and is measured
spectrophotometrically at 340 nm. All results are normalized against quantity of
protein per well, which was quantified using the bicinchoninic acid assay (BCA
assay: Pierce; Rockford, IL).
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2.5

Intracellular Cyclic AMP Accumulation

Cells were harvested into lysis buffer as described above. Intracellular
cyclic AMP accumulation was determined using a commercially available kit from
Enzo Life Sciences (East Farmingdale, NY), according to the manufacturer’s
protocol.
2.6

Fatty Acid Uptake

Cells were washed with calcium/magnesium-free phosphate buffered saline
(CMF-PBS, pH=7.4), incubated with 10 µM BODIPY® FL C16 (4,4-Difluoro-5,7Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Hexadecanoic Acid; Life
Technologies, Carlsbad, CA) in 0.1% FA-Free BSA in Hanks’ balanced salt
solution (HBSS; Gibco – Life Technologies, Carlsbad, CA) for 1 minute, and then
washed twice with an ice-cold solution of 0.2% FA-Free BSA in HBSS.
Fluorescence was measured using a Synergy H1 Multi-Mode Reader (BioTek
Instruments, Inc.; Winooski, VT), and analyzed using Gen5™ Data Analysis
Software (BioTek Instruments, Inc.). The relative BODIPY FL C16 uptake is
expressed as fluorescence intensity per well normalized to the total amount of
protein per well. In separate experiments, cells were incubated in serum-free
DMEM containing 1 mM palmitic acid (500,000 DPM/mL) in 3% BSA for 1
minute, and then washed twice with an ice-cold solution of 0.2% FA-Free BSA in
HBSS. Cells were lysed by incubating with lysis buffer (0.1 M NaOH, 0.2% (w:v)
SDS) at 37°C for two hours. Cell lysates were transferred to a scintillation vial,
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and assessed for radioactivity in a liquid scintillation counter (Tri-Carb 1600 TR
Liquid Scintillation Analyzer, PerkinElmer, Waltham, MA).
2.7

Fatty Acid Oxidation

Fatty acid oxidation (FAO) was assessed by quantifying the production of
14

CO2 from [1-14C] palmitic acid as previously described (237). Cells were plated

in 35 mm dishes, differentiated as described above, and incubated with 10 nM
1,25(OH)2D for 4 days. To measure FAO, dishes were placed and sealed in
wide-mouth jars with screw-top lids, and cells were incubated in serum-free
DMEM containing 1 mM palmitic acid (500,000 DPM/mL) in 3% BSA for 3 hours
at 37ᵒC and 5% CO2. After 3 hours, the reaction was terminated by injection of 5
N perchloric acid to the cell culture dish. To trap 14CO2, 2-phenethylamine was
injected into well inserts containing Whatman 1 filter papers located inside the
jar. After 1 hour, filter papers were placed in vials with scintillation fluid and
assessed for radioactivity in a liquid scintillation counter (Tri-Carb 1600 TR Liquid
Scintillation Analyzer, PerkinElmer, Waltham, MA). Oxidation values were
normalized to the protein content of treatment-matched control dishes.
2.8

De Novo Lipogenesis:

Cells were differentiated in 6-well tissue culture dishes as described
above, and incubated with 10 nM 1,25(OH)2D for 4 days During the last 24 hours
of treatment, 3T3-L1 adipocytes were incubated with 10 mM [13C2]acetate
(Sigma-Aldrich, St. Louis, MO). Cells were harvested into 300 uL lysis buffer
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containing 25 mM HEPES, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100. Lipid
hydrolysis, extraction, derivatization and analysis by high pressure liquid
chromatography/electrospray ionization-mass spectrometry (HPLC/ESI-MS/MS)
were performed as previously described (238). Briefly, cell lysates were heated
at 90ᵒC in a solution of acetonitrile:HCl (37%) (4:1, v/v) to hydrolyze fatty acids.
After cooling to room temperature, fatty acids were extracted with hexane and
dried under nitrogen gas. Fatty acids were resuspended in acetone, derivatized
with 2-bromo-1-methylpyridinium iodide and 3-carbinol-1-methylpyridinium iodide
to form 3-acyloxymethyl-1-methylpyridinium iodide (AMMP), and subjected to
HPLC/ESI-MS/MS analysis. Substrate incorporation into 16:0, 16:1, 18:0, and
18:1 fatty acids was assessed, and data are expressed percent of fatty acid with
13

C label, relative to vehicle. To determine the contribution of glucose as a

substrate for de novo lipogenesis, in separate experiments, 3T3-L1 adipocytes
were incubated in glucose-free DMEM containing a 1:1 mixture of D-[U13

C]glucose (Sigma-Aldrich, St. Louis, MO) and non-labeled D-glucose, at a final

glucose concentration of 4.5 g/L. Incorporation of [U-13C]glucose into fatty acids
during the last 24 hours of treatment was assessed as described above.
2.9

Glucose Uptake and Consumption

Basal and insulin-stimulated glucose uptake were assessed using the 2[1,2-3H(N)]-deoxy-D-glucose uptake assay. Cells were washed with
calcium/magnesium free phosphate buffered saline (CMF-PBS, pH=7.4), and
incubated with serum- and glucose-free DMEM for 2 hours at 37°C and 5% CO2.
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Subsequently, cells were incubated in the presence or absence of insulin (100
nM) for an additional 20 minutes at 37°C, before the 2-[1,2-3H(N)]-deoxy-Dglucose uptake assay was initiated by the addition of serum- and glucose-free
DMEM containing insulin (or vehicle), 2-deoxyglucose (100 µM, Sigma-Aldrich,
St. Louis, MO) and 2-[1,2-3H(N)]-deoxy-D-glucose (1.0 µCi/mL, Perkin Elmer,
Oak Brook, IL). Cells were incubated for a further 10 minutes, and the reaction
was terminated by washing 3 times with ice-cold CMF-PBS containing phloretin
(0.2 mM). Nonspecific uptake, determined in the presence of phloretin (0.2 mM,
Sigma-Aldrich, St. Louis, MO), was subtracted from all values (239). Cells were
lysed by incubating with lysis buffer (0.1 M NaOH, 0.2% (w:v) SDS) at 37°C for
two hours. Cell lysates were transferred to a scintillation vial, and assessed for
radioactivity in a liquid scintillation counter (Tri-Carb 1600 TR Liquid Scintillation
Analyzer, PerkinElmer, Waltham, MA). Glucose uptake values were normalized
to the protein content of treatment-matched control dishes. Glucose
concentrations in spent media samples were measured using a commercially
available kit (Cayman Chemicals, Ann Arbor, MI), utilizing the glucose oxidaseperoxide reaction. Glucose consumption was calculated using the difference
between spent and fresh media samples, and data normalized to total protein.
2.10 Western Blotting

Cells were washed with calcium/magnesium free phosphate buffered
saline (CMF-PBS, pH=7.4) and harvested on ice into lysis buffer containing 25
mM HEPES, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and 1% each of
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protease and phosphatase inhibitor cocktails (Sigma-Aldrich, St. Louis, MO).
Cells were briefly sonicated and cell debris was removed by centrifugation at
12,000 RPM for 15 min at 4°C. Protein concentration was determined using the
BCA assay. Proteins (20–30 μg) were resolved by SDS-PAGE on 7.5%, 10% or
12% polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA). Resolved
proteins were transferred onto nitrocellulose membranes (Bio-Rad Laboratories,
Inc.), and probed with specific antibodies against proteins as indicated. Antigenantibody complexes were detected using the Lumiglo Reagent (Cell Signaling
Technology, Inc.). Densities of immunoreactive bands were assessed using UNSCAN-IT gel analysis software (Silk Scientific, Orem, UT). Densities of the bands
were in the linear range of detectability. Results are expressed as fold change of
respective protein/GAPDH, or phosphorylated protein over total.
2.11 RNA Isolation and Analysis

RNA was isolated using TriReagent (Molecular Research Center,
Cincinnati, OH) according to the manufacturer’s protocol. Reverse transcription
of total RNA was performed using MMLV reverse transcriptase (Promega,
Madison, WI). Real-time quantitative PCR was performed using the Ultra-Fast
SYBR® Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA). The
mRNA abundance of target genes were determined using the threshold cycle
(Ct) value. Data are normalized to 18S expression, and expressed as fold
change relative to vehicle. Primers used are shown in Table 4.

58
2.12 Transfection of 3T3-L1 Adipocytes

The pyruvate carboxylase (PC) plasmid was synthesized and obtained
through OriGene Technologies (Rockville, MD). The PC transcript variant 1 clone
was synthesized, and inserted into the pCMV6-Neo vector downstream of the
cytomegalovirus (CMV) immediate-early promoter. The plasmid was transiently
transfected into differentiated 3T3-L1 adipocytes using Lipofectamine 3000
(Invitrogen, Carlsbad, CA), according to manufacturer protocol.
2.13 Statistical Analysis

Values are presented as mean ± SEM. Results are expressed compared
to vehicle by the Student’s t-test (LSD) or by analysis of variance (ANOVA), with
P<0.05 considered statistically significant. All experiments were performed at
least three times.
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Table 2.1 Primers used in the QPCR analysis of gene expression

Gene
ACC1

ACC2

AQP7

CPT-1α

FAS

GLUT1

GLUT4

hPC

PC

Primer information
Forward: 5'-

GCGTCGGGTAGATCCAGTT-3'

Reverse: 5'-

CTCAGTGGGGCTTAGCTCTG-3'

Forward: 5'-

ACTGTCCTGAGATCCCCCTC-3'

Reverse: 5'-

GGACCCAGTCCTTCAGCTTC-3'

Forward: 5'-

TGTCGCTAGGCATGAACTCC-3'

Reverse: 5'-

CAGGAGATCCCAAGGAGTGG-3'

Forward: 5'-

CTGCAGACTCGGTCACCACT-3'

Reverse: 5'-

ACACCCACCACCACGATAAG-3'

Forward: 5'-

ACCACTGCATTGACGGCCGG-3'

Reverse: 5'-

GGGTCAGGCGGGAGACCGAT-3'

Forward: 5'-

GTGACGATCTGAGCTACGGG-3'

Reverse: 5'-

GAGAGACCAAAGCGTGGTGA-3'

Forward: 5'-

GTGACTGGAACACTGGTCCTA-3'

Reverse: 5'-

CCAGCCACGTTGCATTGTAG-3'

Forward: 5'-

ATGTTGCCCACAACTTCAGCAAGC-3'

Reverse: 5'-

AGTTGAGGGAGTCAAACACACGGA-3'

Forward: 5'-

TCCTCTATCACGTCCTCTGTGT-3'

Reverse: 5'-

ACATTTGGGGAGGCAACAGG-3'
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CHAPTER 3. 1,25-DIHYDROXYVITAMIN D REGULATES TRIACYLGLYCEROL
ACCUMULATION IN 3T3-L1 ADIPOCYTES

3.1

1,25(OH)2D Regulates Lipid Metabolism in 3T3-L1 Adipocytes

3.1.1 1,25(OH)2D Reduces Triacylglycerol Accumulation in 3T3-L1 Adipocytes

Previous studies have demonstrated the ability of 1,25(OH)2D to inhibit the
onset of adipogenic gene expression, and consequent lipid accumulation, during
3T3-L1 preadipocyte differentiation (206, 208, 240). However, whether
1,25(OH)2D impacts lipid metabolism in adipocytes that have completed terminal
differentiation is not known. To determine the impact of 1,25(OH)2D on lipid
metabolism in mature adipocytes that have completed terminal differentiation,
3T3-L1 preadipocytes were first differentiated for 9 days. By Day 9, cells had
achieved complete differentiation, and cells contained large lipid droplets. To
determine whether 1,25(OH)2D modulates triacylglycerol (TAG) accumulation in
mature adipocytes, differentiated cells were stimulated with 1,25(OH)2D (10 nM)
for 4 or 7 days, and total triacylglycerol levels assessed. Following 4 days of
treatment, triacylglycerol accumulation was 21% lower in 1,25(OH)2D-treated
cells compared to vehicle (p=0.01) when normalized to protein content (Figure
3.1). The TAG-lowering effect of 1,25(OH)2D persisted following 7 days of
treatment, demonstrating achievement of a stable state of reduced lipid storage
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(Figure 3.1). Cell viability, assessed using the MTT (Figure 3.2A) and trypan blue
exclusion assays (Figure 3.2B), was not affected following 4 days of 1,25(OH)2D
treatment. These data indicate that 1,25(OH)2D acts on mature adipocytes to
stimulate a reduction in lipid storage in the absence of cytotoxicity.
3.1.2 1,25(OH)2D Stimulates Glycerol Release in 3T3-L1 Adipocytes

Triacylglycerol accumulation in adipocyte lipid droplets is a balance
between storage of fatty acids that are taken up by the cell or synthesized de
novo, and release of fatty acids that are hydrolyzed from TAG by lipolysis.
Hydrolysis of stored TAG in adipocytes by lipolysis allows for the release of fatty
acids from the cell, so that they may be used as an energy source for other
tissues such cardiac and skeletal muscle. Lipolysis is a highly regulated process,
and disturbances in the regulation of this process underlie several metabolic
disorders, including dyslipidemia and insulin resistance (74). To determine
whether 1,25(OH)2D enhances rates of basal lipolysis, glycerol and nonesterified fatty acid (NEFA) release in response to 1,25(OH)2D were assessed.
When triacylglycerol stores are completely hydrolyzed to provide energy
substrates for use by other tissues, glycerol and non-esterified fatty acid moieties
are released from the lipid droplet at a 3:1 molar ratio. While fatty acids may be
re-esterified, oxidized, or released from the cell upon hydrolysis from the lipid
droplet, glycerol kinase activity is negligible in white adipose tissue, meaning that
glycerol released during lipolysis cannot be phosphorylated and used for TAG
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synthesis (76). Therefore, release of glycerol from the cell is frequently used as
an indicator of lipolysis.
Glycerol release was stimulated by 1,25(OH)2D following 1-4 days of
treatment, with a maximal increase of 66% occurring after 2 days (p<0.001)
(Figure 3.3). No change in glycerol release was observed within 1-8 hours of
treatment (data not shown), suggesting genomic or indirect action of 1,25(OH)2D
rather than activation of a rapid signaling pathway. Consistent with an increase in
glycerol release, mRNA expression of the glycerol transporter aquaporin 7
(AQP7) was increased by 27% by 1,25(OH)2D after 2 days (P<0.05) (Figure 3.4).
However, despite a 66% increase in glycerol release with 1,25(OH)2D
treatment, NEFA accumulation in the cell medium was below the limit of
detection in both vehicle- and 1,25(OH)2D-treated cells, and did not change
dramatically with 1,25(OH)2D (data not shown). High rates of fatty acid reesterification occur during lipolysis in WAT; 30-100% of fatty acids in the basal
state, and 10-20% of those freed in response to lipolytic stimuli may be reesterified to TAG in a process termed futile TAG/FA cycling (73, 90-92). These
data suggest that under basal and 1,25(OH)2D-stimulated conditions, either the
majority of fatty acids that are released are either being re-esterified as TAG or
the glycerol that is being released in response to 1,25(OH)2D is not of lipolytic
origin.
To explore the potential impact of 1,25(OH)2D on TAG hydrolysis,
regulators of lipolytic action were investigated. Chemical inhibition of protein
kinase A (PKA) with H-89 dihydrochloride completely prevented 1,25(OH)2D
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stimulation of glycerol release (Figure 3.5A), demonstrating that PKA activity is
necessary for 1,25(OH)2D-stimulated lipolysis or release of glycerol. Additionally,
phosphorylation of hormone sensitive lipase (HSL) at PKA phosphorylation site
Ser660 was significantly increased with 1,25(OH)2D treatment (Figure 3.5B),
while no change in phosphorylation level was observed at the AMPK
phosphorylation site Ser565 (data not shown). Further, despite a reduction in
ATGL protein expression, the protein expression of ATGL cofactor CGI-58 is
significantly increased in response to 1,25(OH)2D treatment (Figure 3.5C).
Given these 1,25(OH)2D-induced changes in the lipolysis signaling
pathway, that the glycerol released in response to 1,25(OH)2D is due to
hydrolysis of TAG remains a possibility. However, not all data are consistent with
1,25(OH)2D stimulation of TAG hydrolysis. First, the reduction in TAG
accumulation after 4 days in response to 1,25(OH)2D cannot quantitatively
sustain the increase in glycerol release that is stimulated by 1,25(OH)2D. As
described above, no increase in NEFA release was observed with 1,25(OH)2D
stimulation. Further, after two days of treatment, during maximal 1,25(OH)2Dstimulated glycerol release, intracellular accumulation of cAMP was not altered
by 1,25(OH)2D (Figure 3.6). PKA activation, which occurs during TAG hydrolysis,
is stimulated by intracellular accumulation of cyclic AMP (cAMP) (241). Lack of
intracellular cAMP accumulation and NEFA release are not consistent with PKAmediated TAG hydrolysis, and collectively, these data suggest that the glycerol
released in response to 1,25(OH)2D is not primarily due to hydrolysis of TAG.
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There are two alternate potential sources of glycerol that could be
contributing to the pool of free glycerol released from the adipocytes. First,
glycerol may be synthesized from glucose during glycolysis. Second, glycerol
may be synthesized from glucose-derived pyruvate or lactate, by a process
called glyceroneogenesis (76). In response to 1,25(OH)2D, whether the released
glycerol is of lipolytic or of glycolytic/glyceroneogenic origin is not yet clear. The
possibility of 1,25(OH)2D stimulation of glycerol release that is of
glycolytic/glyceroneogenic origin is explored further in Chapter 3.2.
3.1.3 1,25(OH)2D Stimulates Fatty Acid Uptake and Oxidation in 3T3-L1
Adipocytes

Another mechanism that can influence TAG accumulation is uptake of
fatty acids. To determine whether 1,25(OH)2D impacts the cells’ ability to take up
exogenous fatty acids, uptake of BODIPY FL C16, a fluorescent C16:0 fatty acid,
was assessed following 1, 2, 3, and 4 days of 1,25(OH)2D stimulation.
Interestingly, despite a net reduction in TAG storage achieved following 4 days of
1,25(OH)2D stimulation, BODIPY fatty acid uptake was significantly increased in
response to 1,25(OH)2D at 24 hours (P<0.05), and remained elevated throughout
the 4 days of treatment (Figure 3.7). These data indicate that 1,25(OH)2D does
not impair the cells’ ability to take up exogenous fatty acids.
In addition, fatty acid balance and changes in TAG accumulation are
influenced by fatty acid oxidation. To determine whether 1,25(OH)2D alters fatty
acid oxidation in 3T3-L1 adipocytes, rates of β-oxidation were measured in
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vehicle- and 1,25(OH)2D-treated cells. To quantify complete oxidation of fatty
acids, 14CO2 production was assessed in response to stimulation by 1 mM
palmitic acid, as described in Materials and Methods. Compared to vehicletreated cells, which exhibited a 14CO2 production rate of 0.624 nmol·hr-1·mg
protein-1, those stimulated with 1,25(OH)2D for four days exhibited a 14CO2
production rate of 1.55 nmol·hr-1·mg protein-1, an increase of 148% (p=0.002)
(Figure 3.8A). This 2.5-fold increase in FAO is interesting, as 1,25(OH)2D
reduces the mRNA expression of the FAO rate-limiting enzyme carnitine
palmitoyltransferase I (CPT-1) by 56% after 4 days (p<0.01), while increasing the
mRNA expression of acetyl-CoA carboxylase 2 (ACC2) by 48% (p=0.02) (Figure
3.8B). When glucose is available, this isoform of ACC is responsible for the
production of malonyl-CoA from glucose-derived acetyl-CoA. Production of
malonyl-CoA inhibits CPT-1, and consequently, oxidation of fatty acids.
Expression of FAO-related genes in response to 1,25(OH)2D are therefore not
indicative of FAO activity in 3T3-L1 adipocytes.
After 4 days of treatment, BODIPY FL C16 uptake was increased by
approximately 1.8-fold in 1,25(OH)2D- vs vehicle-treated cells. At this same time
point, oxidation of exogenously supplied palmitic acid was increased
approximately 2.5-fold by 1,25(OH)2D. To determine if the increase in FAO is a
consequence of increased ability to take up fatty acids, measurement of fatty
acid uptake under the same conditions as those used for FAO experiments was
assessed. In response to 1 mM palmitic acid, [1-14C] palmitic acid uptake was not
significantly different in 1,25(OH)2D- compared to vehicle-treated cells (Figure
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3.8C). A possible explanation for the discrepancy between the impact of
1,25(OH)2D on the uptake of palmitic acid vs. that of BODIPY FL C16 is that
1,25(OH)2D may alter the Km of fatty acid transporters, allowing regulation of
fatty acid uptake to be observed under conditions where fatty acid uptake in
response to increasing extracellular fatty acids is linear. If this is the case, such
regulation may not be observed in response to relatively high fatty acid
concentrations such has the 1 mm palmitic acid used to measure fatty acid
oxidation. Regardless, these data demonstrated that 1,25(OH)2D stimulates fatty
acid oxidation in 3T3-L1 adipocytes, independently of its effect on fatty acid
uptake. This increase in fatty acid oxidation may contribute to the reduction in
TAG accumulation that is observed with 1,25(OH)2D stimulation.
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Figure 3.1. 1,25(OH)2D reduces triacylglycerol accumulation in 3T3-L1
adipocytes. Differentiated 3T3-L1 adipocytes were treated with vehicle or
1,25(OH)2D (10 nM) for 4 or 7 days before analysis as indicated. Triacylglycerol
accumulation in adipocytes was assessed using a commercially available kit.
*P<0.05 compared to vehicle at the same time point (n=3-6/group).
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Figure 3.2. 1,25(OH)2D does not affect cell viability. 3T3-L1 adipocytes were
treated with 1,25(OH)2D (10 nM) for 4 days, and cell viability was assessed using
the MTT (A) and Trypan Blue Exclusion (B) assays (n=6-8/group). No significant
difference in cell viability was observed between vehicle- and 1,25(OH)2D-treated
cells.

69

Figure 3.3. 1,25(OH)2D stimulates glycerol release in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were treated with vehicle or 1,25(OH)2D (10
nM) for 1-4 days as indicated. Glycerol release was assessed in spent media
samples by quantitative enzymatic determination of free glycerol using a
commercially available kit. *P<0.05 compared to vehicle at the same time point
(n=3-6/group).
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Figure 3.4. Aquaglyceroporin mRNA expression is upregulated by 1,25(OH)2D .
Differentiated 3T3-L1 adipocytes were treated with vehicle or 1,25(OH)2D (10
nM) for 2 days. The mRNA expression of glycerol transporter AQP7 is
expressed relative to vehicle. *P<0.05 compared to vehicle (n=3/group).
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Figure 3.5. 1,25(OH)2D-induced glycerol release is PKA-dependent.
Differentiated adipocytes were treated with 1,25(OH)2D (10 nM) or vehicle for 2
days, and then harvested in lysis buffer. A) Inhibition of PKA prevents
1,25(OH)2D-induced glycerol release (n=3/group). B) 1,25(OH)2D stimulates
phosphorylation of HSL at PKA phosphorylation site Serine 660. Phosphorylation
of HSL at the residues indicated was determined by Western blot as described in
Materials and Methods. Data are expressed relative to total HSL protein
expression (n=3/group). C) 1,25(OH)2D regulates CGI-58 and ATGL protein
expression. Data are normalized to expression of actin (n=3/group). *P<0.05
compared to vehicle.
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Figure 3.6. 1,25(OH)2D does not stimulate intracellular cAMP accumulation.
Differentiated 3T3-L1 adipocytes were treated with 1,25(OH)2D (10 nM) or
vehicle for 48 hours. As a positive control, some cells were stimulated with
isoproterenol (10 µM) for two hours prior to harvest. Intracellular cAMP
accumulation was determined as described in Materials and Methods. Data are
normalized to total protein. *P<0.05 compared to vehicle (n=3-6/group).
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Figure 3.7. 1,25(OH)2D stimulates fatty acid uptake in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were treated with 1,25(OH)2D (10 nM) or
vehicle for 1-4 days as indicated. Fatty acid uptake was determined following a 1minute incubation with BODIPY FL C16 (10 µM) as described in Materials and
Methods. The relative BODIPY FL C16 uptake is expressed as fluorescence
intensity per well, normalized to the total amount of protein. *P<0.05 compared to
vehicle at the same time point (n=4/group).
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Figure 3.8. 1,25(OH)2D stimulates fatty acid oxidation in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were stimulated with 1,25(OH)2D (10 nM) or
vehicle for 4 days. A) Complete oxidation of [1-14C] palmitic acid. Fatty acid
oxidation was assessed as described in Materials and Methods (n=4/group). B)
1,25(OH)2D regulates carnitine palmitoyltransferase I (CPT-1) and acetyl-CoA
carboxylase 2 (ACC2) mRNA expression (n=3/group). C) Uptake of [1-14C]
palmitic acid. *P<0.05 compared to vehicle (n=3/group).
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3.2

1,25(OH)2D Regulates Glucose Metabolism and Utilization in 3T3-L1
Adipocytes

3.2.1 1,25(OH)2D Reduces Glucose and Acetate Incorporation into Fatty Acids
in 3T3-L1 Adipocytes:

The previously described studies demonstrate that 1,25(OH)2D stimulates
PKA-dependent glycerol release and oxidation of fatty acids. While it remains
unclear whether the observed glycerol release is of TAG or glyceroneogenic
origin, it is likely that these alterations in lipid metabolism, particularly the
elevated fatty acid oxidation, increase cellular energy expenditure and contribute
to the reduction in TAG accumulation that is stimulated by 1,25(OH)2D. The
studies described within examine the impact of 1,25(OH)2D on glucose
metabolism and utilization in 3T3-L1 adipocytes.
Glucose uptake by adipocytes plays a critical role in the maintenance of
glucose homeostasis (74). In addition to glucose being a source of ATP for the
adipocyte, it is estimated that 20-25% of the glucose consumed by adipocytes is
used for the synthesis of fatty acids (77). To determine whether 1,25(OH)2D
reduces glucose utilization for the synthesis of fatty acids, differentiated 3T3-L1
adipocytes were stimulated with 1,25(OH)2D or vehicle for four days. During the
final 24 hours of 1,25(OH)2D treatment, cell medium was replaced with
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glucose-free DMEM, with D-glucose and D-[U-13C]glucose added at a 1:1 ratio to
a final glucose concentration of 4.5 g/L. Lipid extraction and hydrolysis of fatty
acids were performed as described in Materials andMethods, and incorporation
of the 13C isotope into palmitic, palmitoleic, stearic, and oleic acids was assessed
using HPLC/ESI-MS/MS. These four fatty acids comprise approximately 80% of
the cellular fatty acid pool (242). Compared to vehicle-treated cells, 1,25(OH)2D
stimulated a 28% reduction in 13C incorporation into these fatty acids (p<0.001)
(Figure 3.9), demonstrating a reduced contribution of glucose as a substrate for
de novo lipogenesis. This shift away from glucose utilization for de novo
lipogenesis may contribute to the reduction in TAG that is stimulated by
1,25(OH)2D.
To determine whether 1,25(OH)2D reduces glucose incorporation into fatty
acids by decreasing the rate of fatty acid synthesis in adipocytes, differentiated
3T3-L1 adipocytes were treated as described above, and during the last 24 hours
of treatment cells were incubated with 10 mM [13C2]acetate was added to the cell
culture medium. Cytosolic acetate serves as a substrate for fatty acid synthesis,
and its incorporation into fatty acids serves as an indicator of lipogenesis. Lipid
extraction and hydrolysis of fatty acids were performed as described above, and
[13C2]acetate incorporation into palmitic, palmitoleic, stearic, and oleic acids was
assessed using HPLC/ESI-MS/MS. Compared to vehicle-treated cells, those
stimulated with 1,25(OH)2D exhibited a 9% reduction in acetate incorporation into
fatty acids (p=0.026) (Figure 3.10). This reduction in acetate incorporation into
fatty acids suggests that the enzymatic activity of acetyl CoA carboxylase 1
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(ACC1), the rate-limiting step of lipogenesis, or of fatty acid synthase (FAS), is
inhibited by 1,25(OH)2D. While the mRNA expression of acetyl-CoA carboxylase
1 (ACC1), the ACC isoform responsible for supplying the malonyl-CoA pool for
the synthesis of fatty acids, is not significantly different in vehicle- compared to
1,25(OH)2D-treated adipocytes (Figure 3.11). However, fatty acid synthase (FAS)
mRNA expression is significantly reduced by 1,25(OH)2D (Figure 3.11).
Regardless, the relatively small magnitude of change in acetate compared to
glucose incorporation into fatty acids suggests additional regulation of processes
upstream of fatty acid synthesis by 1,25(OH)2D, at the level of glucose uptake or
oxidation.
3.2.2 1,25(OH)2D Impacts Basal and Insulin-Stimulated 2-deoxglucose Uptake
in 3T3-L1 Adipocytes:

To determine whether 1,25(OH)2D reduces glucose incorporation into fatty
acids by altering glucose uptake in 3T3-L1 adipocytes, glucose uptake was
assessed after 4 days of 1,25(OH)2D treatment using the 2-deoxyglucose uptake
assay as described in Chapter 2 (Materials and Methods). Compared to vehicletreated cells, those stimulated with 1,25(OH)2D exhibited a 62% increase in basal
2-deoxyglucose uptake (p<0.01) (Figure 3.12A). Basal glucose uptake is under
the control of the facilitated diffusion glucose transporter 1 (GLUT1), which is
encoded by the SLC2A1 gene. While the highest levels of GLUT1 expression are
observed in the brain, blood-brain barrier, erythrocytes, and fetal tissues, it is
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expressed ubiquitously in tissues and cell cultures (102, 243). The mRNA
expression of GLUT1 was not changed with 1,25(OH)2D treatment (Figure 3.13).
While basal glucose uptake was significantly higher in 1,25(OH)2Dcompared to vehicle-treated cells, insulin-stimulated 2-deoxyglucose uptake was
not changed with 1,25(OH)2D treatment (Figure 3.12A). Thus, the fold increase in
2-deoxyglucose uptake with acute insulin stimulation, a measure of insulin
sensitivity, was significantly reduced by 28% in response to 1,25(OH)2D (p=0.04)
(Figure 3.12B). Insulin-stimulated glucose uptake in skeletal muscle and adipose
tissue is under the control of the GLUT4 glucose transporter, encoded by the
SLC2A4 gene (102, 243). Consistent with a reduction in insulin sensitivity, mRNA
expression of the insulin-responsive GLUT4 glucose transporter was reduced by
36% in response to 1,25(OH)2D (p=0.01) (Figure 3.13).
In addition to acute basal and insulin-stimulated 2-deoxyglucose uptake,
consumption of glucose and lactate secretion over a 24-hour period were also
assessed. Though rates of basal 2-deoxyglucose uptake were elevated in
response to 1,25(OH)2D, glucose consumption (Figure 3.14A) and lactate
secretion (Figure 3.14B) over 24 hours was not affected. The discrepancy
between the acute 2-deoxyglucose uptake and 24-hour glucose consumption
data may be explained by the substrate concentrations used in each of these two
studies. Under experimental conditions where substrate availability is less than
the saturation concentration for a transporter, such as the 100 µM 2deoxyglucose used for glucose uptake experiments, alterations in the transporter
Km (half-saturation concentration) may be observed. However, under
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experimental conditions where substrate availability exceeds the saturation
concentration for a transporter, such as the 25 mM D-glucose used in glucose
consumption studies, facilitated diffusion of glucose across the membrane is at
maximal capacity under basal conditions. In this case, alterations in GLUT1 Km,
if applicable, would not be detected.
3.2.3 1,25(OH)2D Reduces Pyruvate Carboxylase mRNA Expression

Our data indicate that 1,25(OH)2D reduces the utilization of glucose as a
substrate for de novo lipogenesis, without altering 24-hour glucose consumption.
Previous studies from our laboratory demonstrate that 1,25(OH)2D reduces
glycolysis and glucose flux into the TCA cycle in Harvey-ras oncogene
transfected MCF10A cells, a model of early breast cancer progression, via
negative regulation of the pyruvate carboxylase (PC) gene (unpublished data).
In these transformed breast epithelial cells, the mRNA expression of PC was
reduced by 24% as early as 24 hours, and protein expression was reduced by
25% following 48 hours of 1,25(OH)2D stimulation. Mutation analysis of the PC
promoter suggested the presence and functionality of a negative VDRE,
suggesting that 1,25(OH)2D regulates glucose metabolism via regulation of the
PC gene. These data, along with the those obtained from our current studies,
raised the question of whether 1,25(OH)2D regulates pyruvate carboxylase
metabolism, and thus lipid accumulation, in 3T3-L1 adipocytes.
It has previously been demonstrated that perturbed pyruvate metabolism
impacts triacylglycerol accumulation in 3T3-L1 adipocytes (244). In these studies,
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chemical inhibition of pyruvate carboxylase by 5 and 10 mM phenylacetate
reduced TAG accumulation by 21 and 34%, respectively, after 8 days. Consistent
with inhibition of glycolysis, release of glycerol and lactate were significantly
increased by PC inhibition. Flux estimates indicated that reduced de novo fatty
acid synthesis contributed to the reduction in TAG accumulation. Cytosolic
acetyl-CoA, derived from cleavage of citrate that is exported from the
mitochondria, is required for the synthesis of fatty acids. When de novo fatty acid
synthesis is occurring, the mitochondrial citrate pool becomes drained. The
anaplerotic function of PC is to supply oxaloacetate to the mitochondria TCA
cycle intermediate pool. Therefore, inhibition of PC reduces the amount of
substrate availability for the synthesis of fatty acids. These studies support the
critical role of PC in regulating TAG accumulation.
In our studies, 1,25(OH)2D reduces glucose utilization as a substrate for
fatty acid synthesis. Additionally, 1,25(OH)2D stimulates a 41% reduction in
pyruvate carboxylase mRNA expression in 3T3-L1 adipocytes after 2 days
(p<0.01) (Figure 3.15). It has been demonstrated that PC enzymatic activity
directly correlates with mRNA expression (245). We therefore hypothesized that
1,25(OH)2D reduces glucose incorporation into fatty acids by reducing flux into
the TCA cycle via inhibition of PC enzymatic activity.
To test this hypothesis, the human PC gene was overexpressed in
differentiated 3T3-L1 adipocytes, and glucose incorporation into fatty acids was
assessed. A 6.6-fold increase in PC mRNA abundance was achieved with
transfection of the PC plasmid (Figure 3.16). As expected, overexpression of PC
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significantly increased glucose incorporation into the cellular pool of palmitic,
palmitoleic, stearic, and oleic acids (Figure 3.17), while reducing secretion of
glycerol (Figure 3.18A) and lactate (Figure 3.18B). If 1,25(OH)2D reduces
glucose incorporation into fatty acids by reducing PC enzymatic activity, there
would be no effect of 1,25(OH)2D in PC-overexpressing cells. However, in cells
overexpressing PC, 1,25(OH)2D significantly reduced glucose incorporation into
fatty acids, to levels similar to those in control 1,25(OH)2D-treated cells (Figure
3.17). Moreover, in PC-overexpressing cells, 1,25(OH)2D significantly increased
glycerol (Figure 3.18A) and lactate (Figure 3.18B) secretion, to levels similar of
those observed in control cells. Collectively, these data suggest that 1,25(OH)2D
does not regulate glucose metabolism and subsequent triacylglycerol
accumulation by altering PC enzymatic activity.
3.2.4 Inhibition of Glycolysis Blunts 1,25(OH)2D-Stimulation of Glycerol Release

Previous studies have demonstrated that in the presence of high glucose
concentrations, adipocytes dispose of glucose as lactate and glycerol, potentially
as a defense mechanism against excess energy substrate availability (95, 96).
To determine whether 1,25(OH)2D induces glycerol release by stimulating
hydrolysis of TAG or by stimulating synthesis of glycerol through
glycolysis/glyceroneogenesis, 3T3-L1 adipocytes were stimulated with
1,25(OH)2D in the presence or absence of 2-deoxyglucose (2-DG, 20 mM), an
inhibitor of glycolysis (246, 247). By inhibiting glycolysis, the substrate availability
for synthesis of glycerol via glycolysis and glyceroneogenesis becomes limited.
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Observation of the impact of 1,25(OH)2D under these conditions will help
elucidate whether 1,25(OH)2D stimulates hydrolysis of TAG, or synthesis of
glycerol via glycolysis/glyceroneogenesis.
In vehicle-treated cells, 2-DG stimulated a 3.4-fold increase in glycerol
release within 24 hours (p<0.01) (Figure 3.19). This glycerol is likely derived from
TAG hydrolysis in response to limited ATP availability from glucose. If
1,25(OH)2D stimulates glycerol release by stimulating hydrolysis of TAG, an
additive effect of 1,25(OH)2D on glycerol release would be observed. However,
1,25(OH)2D has no further effect on 2-DG-stimulatd glycerol release after 24
hours, and similar patterns of glycerol release were observed following 2-4 days
of 2-DG and 1,25(OH)2D treatment (Figure 3.19). Collectively, these data are
consistent with 1,25(OH)2D stimulation of glycerol synthesis via glycolysis and/or
glyceroneogenesis, rather than stimulation of TAG hydrolysis.
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Figure 3.9. 1,25(OH)2D reduces glucose incorporation into fatty acids.
Differentiated 3T3-L1 adipocytes were stimulated with 1,25(OH)2D (10 nM) or
vehicle for 4 days. Cells were incubated with D-[U-13C]glucose during the last 24
hours of treatment as described in Materials and Methods, and substrate
incorporation into the cellular pool of palmitic, palmitoleic, stearic, and oleic acids
was assessed using HPLC/ESI-MS/MS. Data are as the percent of labeled fatty
acids containing 13C, relative to vehicle. *P<0.05 compared to vehicle
(n=6/group).

84

Figure 3.10. 1,25(OH)2D reduces acetate incorporation into fatty acids.
Differentiated 3T3-L1 adipocytes were stimulated with 1,25(OH)2D (10 nM) or
vehicle for 4 days. Cells were incubated with [13C2]acetate during the last 24
hours of treatment as described in Materials and Methods, and substrate
incorporation into the cellular pool of palmitic, palmitoleic, stearic, and oleic acids
was assessed using HPLC/ESI-MS/MS. Data are as the percent of labeled fatty
acids containing 13C, relative to vehicle. *P<0.05 compared to vehicle
(n=6/group).
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Figure 3.11. Effect of 1,25(OH)2D on lipogenic gene expression. Differentiated
3T3-L1 adipocytes were treated with vehicle or 1,25(OH)2D (10 nM) for 4 days.
A) The mRNA expression of acetyl CoA carboxylase 1 (ACC1) is not significantly
changed by 1,25(OH)2D. B) 1,25(OH)2D significantly reduces fatty acid synthase
(FAS) mRNA expression. *P<0.05 compared to vehicle (n=3/group).
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Figure 3.12. 1,25(OH)2D stimulates 2-deoxyglucose uptake in 3T3-L1
adipocytes. Differentiated 3T3-L1 adipocytes were treated with 1,25(OH)2D (10
nM) or vehicle for 4 days. A) 2-deoxyglucose uptake was determined following a
20-minute incubation with 2-[1,2-3H(N)]-deoxy-D-glucose (100 µM) as described
in Materials and Methods. 2-deoxyglucose uptake is expressed as nmol•min-1•mg
protein-1, and is normalized to total protein (n=4/group). B) 1,25(OH)2D reduces
insulin sensitivity in 3T3-L1 adipocytes. Data are expressed as fold increase in 2deoxyglucose uptake with acute insulin stimulation, and are normalized to total
protein (n=4/group). *P<0.05 compared to vehicle.
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Figure 3.13. Effect of 1,25(OH)2D on glucose transporter mRNA expression.
Differentiated 3T3-L1 adipocytes were treated with vehicle or 1,25(OH)2D (10
nM) for 4 days. GLUT1 and GLUT4 mRNA are expressed relative to vehicle.
*P<0.05 compared to vehicle (n=3/group).
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Figure 3.14. 1,25(OH)2D does not affect glucose consumption or lactate
secretion in 3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes were treated
with vehicle or 1,25(OH)2D (10 nM) for 1-4 days as indicated. Glucose
concentrations were assessed in spent media samples using a commercially
available kit. Glucose consumption was calculated from the difference between
glucose concentrations in spent and in fresh media samples. Data are expressed
as nmol•min-1•mg protein-1, and are normalized to total protein. No effect of
1,25(OH)2D is observed on glucose consumption at any of the time points tested
(n=3/group).
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Figure 3.15. 1,25(OH)2D reduces pyruvate carboxylase mRNA expression in
3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes were treated with vehicle or
1,25(OH)2D (10 nM) for 2 days. The mRNA expression of pyruvate carboxylase
is expressed relative to vehicle. *P<0.05 compared to vehicle (n=3/group).
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Figure 3.16. Human PC mRNA abundance with PC overexpression.
Differentiated 3T3-L1 adipocytes were transfected with a plasmid containing the
human PC gene as described in Materials and Methods. The mRNA expression
of hPC is expressed relative to control cells. *P<0.05 compared to control
(n=3/group).
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Figure 3.17. Overexpression of pyruvate carboxylase increases glucose
incorporation into fatty acids. Differentiated 3T3-L1 adipocytes were transfected
as described in Materials and Methods. 24 hours following transfection with the
PC or control plasmid, cells were stimulated with 1,25(OH)2D (10 nM) or vehicle
for 4 days. Cells were incubated with D-[U-13C]glucose during the last 48 hours of
treatment as described in Materials and Methods, and substrate incorporation
into the cellular pool of palmitic, palmitoleic, stearic, and oleic acids was
assessed using HPLC/ESI-MS/MS. Data are as the percent of labeled fatty acids
containing 13C, relative to vehicle. *P<0.05 compared to vehicle (n=3/group).
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Figure 3.18. Overexpression of pyruvate carboxylase reduces glycerol and
lactate secretion. Differentiated 3T3-L1 adipocytes were transfected as
described in Materials and Methods. 24 hours following transfection with the PC
or control plasmid, cells were stimulated with 1,25(OH)2D (10 nM) or vehicle for 2
days. Glycerol (A) and lactate (B) release were assessed in spent media
samples as described in Materials and Methods. Bars with different letters are
significantly different (P<0.05) (n=3/group).
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Figure 3.19. Inhibition of glycolysis blunts 1,25(OH)2D-stimulation of glycerol
release in 3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes were co-treated
with 1,25(OH)2D (10 nM) and 2-deoxyglucose (20 mM) for 2 days. Glycerol
release was assessed in spent media samples by quantitative enzymatic
determination of free glycerol using a commercially available kit. *P<0.05
compared to vehicle at the same time point (n=3/group).
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CHAPTER 4. DISCUSSION

As the prevalence of obesity across age, ethnic, and socioeconomic
groups increase, so does the need to identify safe and effective measures by
which we can prevent and reverse the disease. Both hypertrophy (increase in cell
size) and hyperplasia (increase in cell number) have been targeted as pathways
that might be modulated in an attempt to ameliorate the progression of obesity
and associated metabolic disorders. While both of these pathways contribute to
the maintenance of white adipose tissue, a study by Spalding et al. demonstrate
that changes in fat mass, even in cases of significant weight gain or loss, are due
to changes in adipocyte size rather than alterations in adipose cell number (105).
In this study, Spalding et al. observed an annual adipocyte turnover rate of 10%,
independent of age and BMI, yielding an average adipocyte lifespan of
approximately 10 years. These data highlight the significance that regulation of
lipid accumulation in existing adipocytes plays in the modulation of adipose
mass.
Observation of the inverse relationship between vitamin D status and
measures of adiposity in humans has triggered a high level of interest in the
relationship between vitamin D and obesity. Many studies have been conducted
to determine the impact of vitamin D on adipogenesis, or differentiation of
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adipocytes; however, there is little knowledge of the impact of vitamin D on lipid
storage and metabolism in differentiated adipocytes. In the present studies,
1,25(OH)2D stimulated a significant reduction in TAG accumulation in
differentiated 3T3-L1 adipocytes. We demonstrate that mitochondrial β-oxidation
is stimulated by 1,25(OH)2D in these adipocytes, and the data suggest that
1,25(OH)2D stimulates a reduction in the utilization of glucose for fatty acid
synthesis, while increasing glucose utilization for the synthesis and secretion of
glycerol. To our knowledge, these results are the first to demonstrate directly that
1,25(OH)2D alters fatty acid synthesis and oxidation in differentiated adipocytes.
It is well-established that vitamin D is stored in adipose tissue, and as a
result, many studies have been performed to determine the impact of vitamin D
on adipogenesis, or hyperplasia. Studies utilizing the 3T3-L1 preadipocyte cell
line found that 1,25(OH)2D inhibits differentiation of these cells, and subsequent
lipid accumulation, by downregulating differentiation “master regulator” PPARγ
and C/EBPα (205-208). Downregulation of these genes inhibits the subsequent
expression of genes necessary for lipid and glucose metabolism, and
consequently, preservation of the preadipocyte phenotype. However, the impact
of vitamin D on adipocyte differentiation remains controversial. While 1,25(OH)2D
inhibits the differentiation of murine 3T3-L1 adipocytes, 1,25(OH)2D stimulates
maturation and lipid accumulation during the adipogenic differentiation of porcine
mesenchymal stem cells (212) and human subcutaneous preadipocytes (213).
The discrepancy between these different cell lines, while not fully understood,
may be attributed to the different roles that adipose tissue plays with regard to
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energy balance in these species, or due to the stage of differentiation that
isolated human subcutaneous adipocytes are in compared to the 3T3-L1
preadipocyte cell line.
Reports of vitamin D regulation of lipid metabolism and accumulation in
differentiated adipocytes are limited. One study performed by Zoico et al. (248)
examined the impact 1,25(OH)2D on the lipopolysaccharide (LPS)- induced
inflammatory response in 3T3-L1 adipocytes that had been differentiated for 5
days. In this study, stimulation with LPS (1.0 µg/mL) for 24 hours triggered a
significant increase in the secretion of pro-inflammatory adipokines IL-6 and
TNFα, with a concomitant increase in lipid accumulation, measured by Oil Red-O
staining. However, when differentiated 3T3-L1 adipocytes were pre-treated with
1,25(OH)2D (100 nM) for 24 hours, the LPS-induced increases in cytokine
secretion and lipid accumulation were attenuated. These data suggest a role for
vitamin D in the regulation of inflammation-mediated lipid metabolism; however,
no impact of 1,25(OH)2D was observed on lipid accumulation in the absence of
LPS-induced inflammation.
In contrast to the null results described by Zoico et al. with regard to the
impact of 1,25(OH)2D on lipid accumulation in a non-inflammatory state, a recent
study published by Chang and Kim documented a reduction in lipid accumulation
in 3T3-L1 adipocytes with 1,25(OH)2D stimulation (249). In these studies, 3T3-L1
adipocytes that had been differentiated for 6 or 7 days were stimulated for 24
hours with 1-100 nM 1,25(OH)2D (249). An approximate 15% reduction in lipid
accumulation, measured by Oil Red O staining, was observed following 24 hours
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of 1 nM 1,25(OH)2D stimulation, with similar reductions in lipid accumulation
occurring with 10 and 100 nM 1,25(OH)2D treatment. Consistent with the studies
described in this dissertation, Chang and Kim observed a significant increase in
basal glycerol release with 24 hours of 1,25(OH)2D treatment, and the authors
report 1,25(OH)2D enhancement of isoproterenol-induced glycerol release.
Further, the mRNA expression of lipogenic genes (C/EBPα, FAS, PPARγ, SCD1) were significantly reduced by 1,25(OH)2D, while lipid oxidizing genes (CPT-1,
PGC-1α, PPARα, UCP-1) were significantly increased following 1,25(OH)2D
stimulation. These 1,25(OH)2D-induced changes in lipid accumulation and lipid
metabolizing gene expression occurred with a concomitant increase in sirtuin-1
(SIRT1) mRNA expression and activity. SIRT1 promotes fatty acid mobilization
from adipose tissue (250), and these data suggest that 1,25(OH)2D may reduce
lipid accumulation in 3T3-L1 adipocytes by activating this metabolic pathway.
However, 1,25(OH)2D regulation of adipocyte lipid accumulation remains far from
fully understood.
While the studies described by Chang and Kim provide some insight into
the actions of 1,25(OH)2D in adipocytes, the role of 1,25(OH)2D in regulating
adipose function and pathophysiology remain incompletely defined. The authors
report an increase in NAD/NADH ratio and SIRT1 activity with 1,25(OH)2D
treatment (249). SIRT1 acts as a metabolic sensor, acting in coordination with
AMPK to increase oxidative capacity in tissues such as skeletal muscle (251),
and promote lipid mobilization from adipose tissue to support fatty acid oxidation
in peripheral tissues (250). As AMPK is known to activate SIRT1 by increasing
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the NAD/NADH ratio (252), it would have been interesting to know if 1,25(OH)2D
stimulates activation of AMPK in these cells as well. Further, given the extensive
history of discrepancies between 1,25(OH)2D action in vitro and the impact of
dietary vitamin D on adipose tissue in vivo (215), it would have been valuable if
functional outcomes such as fatty acid oxidation and fatty acid synthesis had
been measured in these studies directly, rather than relying on the mRNA
expression of genes related to FA metabolism alone to determine the impact of
1,25(OH)2D on adipose tissue physiology.
As the available evidence regarding the impact of vitamin D on
differentiated adipocytes remains limited, the collective aim of the present studies
was to determine the impact of 1,25(OH)2D on lipid metabolism and storage in
3T3-L1 adipocytes. In these studies, we observed a 21% reduction in TAG
accumulation after 4 days of stimulation with 10 nM 1,25(OH)2D (Figure 3.1).
This reduction in TAG accumulation persisted for up to 7 days, and was achieved
without negatively impacting cell viability (Figure 3.2). In addition to the reduction
in TAG accumulation, we found that 1,25(OH)2D stimulates glycerol release after
1-4 days, with a maximal increase in glycerol release following 48 hours of
treatment (Figure 3.3). These data are consistent with the recently published
study by Chang and Kim, who demonstrate a significant increase in glycerol
release and reduction in lipid accumulation following 24 hours of 10 nM
1,25(OH)2D treatment (249).
Typically, glycerol release is indicative of lipolysis. However, while several
changes in the lipolysis signaling pathway were observed in response to
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1,25(OH)2D, collectively, the data obtained from the current studies do not
suggest that 1,25(OH)2D stimulates TAG hydrolysis. Consistent with TAG
hydrolysis, 1,25(OH)2D-induced glycerol release is abolished upon chemical
inhibition of PKA (Figure 3.5A). Further, 1,25(OH)2D stimulates increased
phosphorylation of HSL at PKA phosphorylation site Ser660 (Figure 3.5B), and
interestingly, an increase and decrease in ATGL and CGI-58 protein expression,
respectively (Figure 3.5C). Previous studies have demonstrated that retroviralmediated overexpression of ATGL increases basal glycerol and NEFA release in
3T3-L1 adipocytes, while siRNA-mediated knockdown of ATGL has the opposite
effect (253). Given the increase in basal glycerol release by 1,25(OH)2D,
downregulation of ATGL protein expression is contrary to what might be
expected. However, ATGL requires activation by CGI-58 to hydrolyze TAG, and it
has been demonstrated that the molar ratio of CGI-58:ATGL is positively
associated with ATGL hydrolase activity (85). Therefore, the increase in CGI-58
protein expression in concert with downregulation of ATGL protein expression
results in an elevated CGI-58:ATGL molar ratio, and consequently, is consistent
with elevated glycerol release.
While these changes in the lipolysis signaling pathway suggest that
1,25(OH)2D may stimulate glycerol release by hydrolyzing TAG, not all data are
consistent with this hypothesis. First, the reduction in TAG accumulation that is
achieved following 4 days of 1,25(OH)2D treatment (-0.514 µmols, based on an
average TAG mw of 846.09 g/mol) does not quantitatively account for the
increase in the number of moles of glycerol that are secreted following 1-4 days
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of 1,25(OH)2D stimulation (+29.68 µmols). Further, while glycerol release is
typically indicative of lipolysis, as complete TAG hydrolysis yields NEFA and
glycerol moieties in a 3:1 molar ratio, no increase in NEFA release was observed
with 1,25(OH)2D (data not shown). Finally, intracellular cAMP levels, which
become elevated in response to lipolytic stimuli in order to activate PKA, were
not changed following 1,25(OH)2D treatment (Figure 3.6). These data suggest
that 1,25(OH)2D may stimulate stimulates glycerol synthesis from glycolytic or
glyceroneogenic precursors, rather than hydrolysis of TAG. Previous studies
have demonstrated that adipocytes dispose of glucose as glycerol, particularly in
response to high glucose concentrations (95) such as the standard culture
medium used in these studies.
To test the hypothesis that 1,25(OH)2D stimulates synthesis of glycerol
from glycolytic/glyceroneogenic precursors, adipocytes were co-treated with
1,25(OH)2D and 2-deoxyglucose, a known inhibitor of glycolysis. Inhibition of
glycolysis completely prevented 1,25(OH)2D stimulation of glycerol release in
3T3-L1 adipocytes (Figure 3.19). Since lactate, the primary substrate for
glyceroneogenesis in adipocytes, is produced from pyruvate obtained through
glycolysis, this assay is not capable of distinguishing between glycerol produced
from non-glucose precursors (glyceroneogenesis) or directly from glucose
(glycolysis). However, these data do suggest that 1,25(OH)2D stimulates
synthesis of glycerol via one of these pathways, rather than hydrolysis of TAG.
These data also highlight the possibility of altered glucose metabolism in
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response to 1,25(OH)2D, and the potential contribution of de novo lipogenesis to
the 1,25(OH)2D-induced reduction in TAG accumulation.
In the current studies, 1,25(OH)2D reduced glucose incorporation into fatty
acids by 30% compared to vehicle-treated cells (Figure 3.9), without altering the
rate of glucose consumption (Figure 3.14A). To determine whether the reduction
in glucose incorporation into fatty acids was a consequence of an impaired ability
to synthesize fatty acids, in separate experiments, acetate incorporation into fatty
acids was also measured. Acetate incorporation into fatty acids, a measure of
fatty acid synthesis, was reduced by only 10% in response to 1,25(OH)2D (Figure
3.10). These data suggest that while fatty acid synthesis is slightly inhibited in
response to 1,25(OH)2D, possibly via reduced enzymatic activity of fatty acid
synthase and/or acetyl-CoA carboxylase, 1,25(OH)2D stimulates a reduction in
the utilization of glucose specifically for the synthesis of fatty acids. As glucose
consumption (Figure 3.14A) and lactate secretion (Figure 3.14B) were not
impacted following 1-4 days of treatment, the reduction of glucose incorporation
into fatty acids is consistent with adipocytes disposing of excess glucose as
glycerol. The possibility that 1,25(OH)2D stimulates glucose disposal as glycerol
as a consequence of reduced glucose flux into the TCA cycle was explored.
As 1,25(OH)2D reduced the utilization of glucose for fatty acid synthesis, it
is possible that 1,25(OH)2D reduces flux of glucose into the TCA cycle. By
entering into the TCA cycle, glucose-derived pyruvate serves as a source of
ATP. Additionally, by replenishing TCA cycle intermediates, pyruvate supplies
carbon substrate in the form of acetyl-CoA for fatty acid synthesis. Previous
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studies by our laboratory demonstrate that 1,25(OH)2D reduces pyruvate
carboxylase expression and enzymatic activity in human breast epithelial cells,
leading to reduced glycolysis and glucose flux into the TCA cycle (unpublished
data). Consistent with these studies, results from the current studies demonstrate
that 1,25(OH)2D reduces PC mRNA expression in 3T3-L1 adipocytes (Figure
3.15). To determine whether 1,25(OH)2D reduces glucose utilization as a
substrate for fatty acid synthesis, and consequently TAG accumulation, by
reducing pyruvate carboxylase activity, human PC (hPC) was overexpressed in
differentiated 3T3-L1 adipocytes. Despite a 6.5-fold increase in PC mRNA
expression, PC overexpression failed to inhibit 1,25(OH)2D-induced changes in
glycerol release (Figure 3.18A) and glucose incorporation into fatty acids (Figure
3.17), suggesting that PC does not mediate the 1,25(OH)2D-induced changes in
fatty acid synthesis and accumulation. Whether 1,25(OH)2D stimulates reduced
glucose flux into the TCA cycle remains to be determined. Collectively, the
available data do suggest that 1,25(OH)2D does stimulate glucose disposal as
glycerol.
The impact of elevated glycerol release may have implications in hepatic
gluconeogenesis and systemic glucose homeostasis. Glycerol and lactate are
the major substrates for hepatic gluconeogenesis, and under fasted conditions,
glycerol release from adipocytes by lipolysis is a major contributor to hepatic
glucose synthesis (254). Previous studies have demonstrated that glycerol
delivery to the liver can stimulate hepatic glucose production by a substratedependent push mechanism, independent of insulin signaling (255-257). Since
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hepatic gluconeogenesis is a major contributor to the hyperglycemia that is
observed in type 2 diabetes (258), this raises the concern about the impact of
1,25(OH)2D-stimulated glycerol release in adipocytes in vivo. However, many
cross-sectional studies have reported a positive relationship between vitamin D
status and insulin sensitivity (259), as well as a positive impact of vitamin D on
hepatic glucose and lipid metabolism (260). While overall the existing evidence
does not support that vitamin D supplementation improves insulin sensitivity in an
insulin-resistance state (187), the available evidence does suggest that it unlikely
that vitamin D action in adipocytes disrupts global glucose homeostasis in
humans.
In the current studies, FA oxidation was increased approximately 2.5-fold
by 1,25(OH)2D in 3T3-L1 adipocytes (Figure 3.8A). This is, to our knowledge, the
first report of increased fatty acid oxidation in response to 1,25(OH)2D in white
adipocytes. While no reports of vitamin D stimulation of fatty acid oxidation in
white adipocytes have been made, a few studies have documented evidence that
vitamin D may play a role in fatty acid oxidation in other tissues, and contribute
positively to the maintenance of energy homeostasis. A study by Marcotorchino
et al. examined the effect of dietary vitamin D on high fat diet-induced weight
gain and glucose homeostasis in C57BL/6 mice (261). In this study, despite no
difference in energy intake between mice given a high fat diet with standard
vitamin D (1,500 IU/kg food, HF) and those given a high fat diet with high vitamin
D (15,000 IU/kg food, HFVD), HFVD mice gained significantly less body and
adipose mass than HF mice after 10 weeks. The authors found that HFVD mice
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had a significantly lower respiratory quotient, and increased energy expenditure
and lipid oxidation compared to HF mice, reflecting the preferential use of lipids
vs. carbohydrates as an energy source. Gene expression of enzymes related to
fatty acid oxidation were elevated in BAT, liver, and skeletal muscle of HFVD
compared to HF mice. While fatty acid oxidation was not examined in white
adipose tissue specifically, these data do demonstrate the ability of vitamin D to
increase global energy expenditure, and consequently, protect against excessive
accumulation of adipose tissue. The data obtained by Marcotorchino et al. and
those described from the current studies both provide mechanistic support for the
inverse relationship between vitamin D and obesity.
In addition to the global impact of dietary vitamin D on fatty acid oxidation
described above, vitamin D has been reported to increase FAO and reduce FA
synthesis specifically in hepatocytes (262). In this study, male Sprague-Dawley
rats were fed a control diet, or a high fat diet plus intraperitoneal injection of 1,
2.5, or 5 µg/kg 1,25(OH)2D. Administration of 1,25(OH)2D ameliorated HF dietinduced body and liver weight gain, increased the hepatic mRNA expression of
FAO-related genes (PPARα and CPT-1), and reduced the hepatic mRNA
expression of genes involved in lipogenesis (SREBP-1c, ACC, FAS). These data
suggest that 1,25(OH)2D protects against hepatic steatosis by stimulating FAO,
while inhibiting lipogenesis in the liver. Again, these data highlight the role of
vitamin D in the regulation of energy expenditure and lipid homeostasis, and
provide mechanistic support of the inverse relationship between vitamin D and
obesity. However, it must be noted that the studies described by Marcotorchino
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et al. (261) and Yin et al. (262) examined only the impact of vitamin D (dietary or
intraperitoneal injection of 1,25(OH)2D, respectively) on high fat diet-induced
weight gain and metabolism, without including a control group to examine the
impact of vitamin D on energy and lipid metabolism in the non-obese state. Such
studies are essential in order to fully understand the impact of vitamin D on lipid
oxidation and metabolism.
The studies described above demonstrate that vitamin D may impact lipid
oxidation in oxidative tissues such as the liver, skeletal muscle, and BAT.
However, very limited data exist regarding the impact of fatty acid oxidation in
WAT. While β-oxidation is most well-studied in these oxidative tissues, oxidative
capacity in adipocytes is reduced during obesity and in the diabetic state (263,
264), and targeting oxidative metabolism in WAT is an effective treatment
measure in type 2 diabetes (265, 266). Consistent with our observation of
increased β-oxidation with 1,25(OH)2D stimulation, the recent report by Chang
and Kim demonstrates that 1,25(OH)2D stimulates the mRNA expression of
several genes related to fatty acid oxidation in 3T3-L1 adipocytes, including CPT1α, PGC1α, UCP-1, and PPARα, providing additional support that vitamin D may
increases FAO in these cells (249).
This increase in fatty acid oxidation that was observed in the present
studies is interesting, given the reduction in CPT-1 mRNA expression, and
increase in ACC1 mRNA expression, in response to 1,25(OH)2D (Figure 3.8B).
Flux of the β-oxidation pathway is determined primarily by CPT-1 (267, 268) and
by substrate supply (267, 269). When cellular energy stores are low, AMPK
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phosphorylates ACC, thereby inactivating it (270). This phosphorylation event
inhibits ACC-mediated production of malonyl-CoA, a potent CPT-1 inhibitor,
allowing ATP-yielding processes such as β-oxidation to occur, while limiting ATPconsuming processes such as de novo lipogenesis. Conversely, during times of
adequate cellular energy states, ACC1 remains in its active, unphosphorylated
state, producing malonyl-CoA for the synthesis of fatty acids, and inhibiting the
ATP-producing process of β-oxidation. As ACC1 is regulated primarily by
phosphorylation rather than transcriptionally, its mRNA levels in the cell may not
necessarily reflect its enzymatic activity. These findings are significant, given that
many of the previously described studies of 1,25(OH)2D action on adipocytes
report only changes in the mRNA expression of lipogenic and oxidative enzymes,
without examining enzyme functionality or activity. For example, the impact of
1,25(OH)2D on CPT-1 expression described herein is in contrast to the findings
described by Chang and Kim, who report a significant increase in CPT-1 mRNA
expression in 3T3-L1 adipocytes in response to 1,25(OH)2D (249). Nonetheless,
the data from both the current studies and those described by Chang and Kim
are consistent with 1,25(OH)2D stimulation of fatty acid oxidation in differentiated
3T3-L1 adipocytes.
To determine if 1,25(OH)2D reduces TAG accumulation in 3T3-L1
adipocytes by inhibiting the uptake of exogenous fatty acids, the impact of
1,25(OH)2D on uptake of the fluorescent C16 BODIPY fatty acid was observed.
Despite the observed reduction in TAG accumulation, uptake of the C16 BODIPY
fatty acid was elevated in response to 1,25(OH)2D (Figure 3.7). These data
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suggest that 1,25(OH)2D enhances the adipocyte’s ability to take up exogenous
fatty acids. However, under the experimental conditions used for these studies,
the contribution of exogenous fatty acids to the intracellular TAG pool remains
limited. In these experiments, exogenous fatty acids were not directly supplied
during or after differentiation. Rather, the contribution of exogenous lipids to the
intracellular TAG pool was limited to the amount of fatty acids that were present
in the cell culture sera, supplied in the culturing media in a 10% (vol:vol) ratio. In
an environment where exogenous fatty acids are more freely or frequently
available, such as those found in circulation in vivo postprandially, the
contribution of exogenous lipids to intracellular TAG pool may be significantly
larger, and may impact the overall effect of 1,25(OH)2D on TAG accumulation in
vivo.
It is established that long-chain fatty acids (LCFA) stimulate FAO by acting
as PPAR ligands, stimulating the transcription of lipid-oxidizing genes (271). As
1,25(OH)2D stimulates uptake of BODIPY FL16 in 3T3-L1 adipocytes, the
possibility that FAO is increased indirectly by 1,25(OH)2D, as a result of
increased uptake of 1-14C-palmitate, was raised. To address this question,
uptake of 1-14C-palmitate was determined under conditions used for the FAO
assay. Under these conditions, uptake of 1-14C-palmitate is not different between
vehicle- and 1,25(OH)2D-treated cells (Figure 3.8C). The discrepancy between
uptake of BODIPY fatty acid and 1-14C-palmitate may be due to the difference in
substrate concentration used in each of these assays. As fatty acid uptake
occurs via both diffusion and protein-mediated uptake (71), it is likely that at low
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substrate concentrations, such as those used for the BODIPY FA uptake assay,
differences in protein mediated uptake may be observed. Conversely, under
conditions of high substrate availability, protein-mediated and passive diffusion of
fatty acids across the cell membrane are maximized, and differences in proteinmediated uptake may not be detected. Since no difference in 1-14C-palmitate
uptake was observed between vehicle- and 1,25(OH)2D-treated cells, it is
unlikely that indirect stimulation of FAO by increased FA uptake is the
mechanism by which 1,25(OH)2D stimulates FAO in these cells.
The data from these studies demonstrate that 1,25(OH)2D acts in
differentiated adipocytes to regulate lipid and glucose metabolism, leading to
reduced TAG accumulation. While the impact of vitamin D supplementation on
weight loss remains controversial (272), these data provide mechanistic support
for the inverse relationship between vitamin D status and measures of adiposity.
However, studies to determine the clinical significance of these findings are
needed. Many in vitro studies have been performed to determine the impact of
vitamin D on adipose tissue physiology, specifically, on adipocyte differentiation,
but the impact of 1,25(OH)2D on adipogenesis in humans is still unclear.
1,25(OH)2D inhibits adipogenesis in murine 3T3-L1 preadipocytes, while
promoting differentiation in human preadipocytes and primary mouse adipocytes
at an advanced stage of differentiation (272). These data suggest that the impact
of 1,25(OH)2D on adipogenesis is dependent on stage of differentiation. On the
other hand, while limited in quantity and restricted to the 3T3-L1 cell line, the
available evidence regarding 1,25(OH)2D regulation of already differentiated
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adipocytes consistently demonstrate that 1,25(OH)2D reduces lipid accumulation
in these cells, at least in part by regulating metabolic pathways that are
independent of the signaling pathways that control early adipogenesis. Whether
1,25(OH)2D has the same impact on differentiated human adipocytes remains to
be determined.
That 1,25(OH)2D modulates adipocyte metabolism and lipid storage
independently from its effects on the adipogenic program highlights the potential
for vitamin D to impact adipose tissue physiology through its effects on existing
adipocytes, in addition to its potential effects on differentiation of preadipocytes
and mesenchymal stem cells. This may have therapeutic potential, as significant
changes in adipose mass are mainly due to alterations in cell size rather than cell
number (105). It has been demonstrated that adipocyte size is positively
correlated with serum insulin and leptin concentrations, insulin resistance, and
risk of developing type 2 diabetes (273-281). Obese individuals with few, large
adipocytes are more glucose intolerant and hyperinsulinemic than those having
the same degree of adiposity but in many small adipocytes (276-278, 282).
Further, large adipocyte size may impair adipose function by promoting local
inflammation and altered adipokine secretion (283-287). These data suggest that
for a given state of adiposity, a higher number of smaller adipocytes is more
metabolically favorable than fewer, larger adipocytes.
Given that it is more metabolically favorable to distribute adipose mass
over a larger number of smaller adipocytes, agents such as 1,25(OH)2D that
reduce adipocyte size by reducing accumulation in existing (differentiated)
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adipocytes, or possibly by distributing the existing fat mass over a larger number
of adipocytes through stimulation of adipogenesis, may be beneficial in
preserving metabolic function. In support of this, a study by Caron-John et al.
demonstrated that in women undergoing abdominal gynecological surgery, intake
of vitamin D was inversely correlated with omental adipocyte size, independent of
calcium intake, BMI, total body fat mass, season, and physical activity.(288). In
this study, Serum 25(OH)D was also negatively correlated with omental
adipocyte size, and with total fat mass. Dietary intakes of vitamin D, calcium, and
dairy products were assessed using a food frequency questionnaire, and mean
adipocyte size was calculated by measuring the diameter of 250 adipocytes per
patient. These data provide support for vitamin D regulation of adipose tissue
physiology in humans, and highlight a potential mechanism by which dietary
vitamin D may protect against obesity-associated metabolic disorders.
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS

5.1

Conclusions

In conclusion, 1,25(OH)2D impacts several processes related to fatty acid
and glucose metabolism in differentiated 3T3-L1 adipocytes, leading to reduced
TAG accumulation. 1,25(OH)2D stimulates glycerol release, likely due to
stimulation of glycerol synthesis from glucose-derived substrates (e.g. during
glycolysis, or from lactate or pyruvate). Fatty acid uptake and oxidation are
stimulated by 1,25(OH)2D, while glucose utilization as a substrate for fatty acid
synthesis is reduced. Collectively, these changes in adipocyte metabolism may
contribute to the reduction in TAG accumulation that is stimulated by 1,25(OH)2D.
The results of this study may aid in the identification of metabolic pathways
targeted by 1,25(OH)2D, and in the development of in vivo studies designed to
examine the impact of dietary vitamin D on obesity and related metabolic
disorders.
5.2

Future Directions

While the studies described herein improve our understanding of vitamin D
regulation of adipose tissue metabolism, several questions remain regarding
vitamin D impact on adipose tissue metabolism and function.
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First, the studies described in this dissertation utilized the murine 3T3-L1
preadipocyte cell line to examine the impact of 1,25(OH)2D on glucose and lipid
metabolism and TAG accumulation in adipocytes. Given the discrepancies in
1,25(OH)2D action on preadipocyte differentiation between mouse and human
preadipocytes, it will be essential to examine the impact of 1,25(OH)2D on energy
substrate metabolism and TAG accumulation in differentiated human adipocytes.
The discrepancy in 1,25(OH)2D action between mouse and human preadipocytes
may be due to differing actions of 1,25(OH)2D on the adipogenic transcriptional
cascade, and may be dependent on the stage of differentiation that the cell is in.
Therefore, the impact of 1,25(OH)2D on human adipocyte metabolism after the
differentiation program is complete will need to be studied directly. This
knowledge is key in understanding the vitamin D regulation of adipose tissue in
humans.
Second, it will be useful to determine the minimum concentration of
1,25(OH)2D necessary to elicit changes in glucose and lipid metabolism, and in
TAG accumulation in adipocytes. The concentration of 1,25(OH)2D used in the
current studies (10 nM) was chosen in order to ensure the ability to capture the
cellular response to 1,25(OH)2D stimulation. While adipose tissue concentrations
of 1,25(OH)2D and rate of local adipose production of 1,25(OH)2D are not known,
serum 1,25(OH)2D concentrations are generally in the picomolar range. Chang
and Lee demonstrated that 1,25(OH)2D reduces neutral lipid accumulation in
concentrations as low as 1 nM (249), suggesting that the 1,25(OH)2D-induced
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changes in glucose and lipid metabolism may also occur at lower 1,25(OH)2D
concentrations.
Finally, the impact of dietary vitamin D on adipocyte metabolism and
substrate handling must be examined in vivo. A study designed to examine: 1)
whether dietary vitamin D may elicit changes in adipose tissue metabolism and
total fat mass that are consistent with the current in vitro studies (e.g. elevated
glycerol release and fatty acid oxidation in adipose tissue); and 2) the impact of
altered adipose metabolism on systemic energy balance, lipid profile, and
glucose homeostasis. It is possible that chronically elevated glycerol supplied to
the liver by adipose tissue would stimulate gluconeogenesis leading to elevated
fasting blood glucose. However, this scenario is unlikely, given the positive
association between vitamin D status and insulin sensitivity (259), and the
favorable impact of high dietary vitamin D on liver glucose and lipid metabolism
(260). While several questions remain to be answered, the studies described in
this dissertation provide information that is critical to improve our understanding
of the actions of 1,25(OH)2D on adipose tissue metabolism and function, and that
provides mechanistic support for the inverse relationship between vitamin D
status and obesity.
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